Distribution volume ratios without blood sampling from graphical analysis of PET data

DOI: 10.1097/00004647-199609000-00008
Journal of Cerebral Blood Flow and Metabolism, 1996, 16, 834-40.

#	Paper	IF	Citations
1297	Quantitative comparison of 3D and 2D PET with brain studies.		
1296	Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. **1997**, 6, 279-87		883
1295	Cocaine abusers do not show loss of dopamine transporters with age. **1997**, 61, 1059-65		35
1294	Concentration and occupancy of dopamine transporters in cocaine abusers with [11C]cocaine and PET. **1997**, 27, 347-56		43
1293	Age-dependent decline of dopamine D1 receptors in human brain: a PET study. **1998**, 30, 56-61		175
1292	Positron emission tomography (PET) methodology for small animals and its application in radiopharmaceutical preclinical investigation. **1998**, 25, 729-32		36
1291	N-[11C]methylspiperone PET, in contrast to [11C]raclopride, fails to detect D2 receptor occupancy by an atypical neuroleptic. **1998**, 82, 147-60		25
1290	Comparison of FORE, OSEM and SAGE algorithms to 3DRP in 3D PET using phantom and human subject data.		1
1289	Studies of the effects of ECT on the dopamine receptors. **1998**, 7, S234		
1288	Loss of D2 receptor binding with age in rhesus monkeys: importance of correction for differences in striatal size. *Journal of Cerebral Blood Flow and Metabolism*, **1999**, 19, 218-29	7.3	57
1287	Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study. **1999**, 46, 723-31		53
1286	Striatal uptake of a novel PET ligand, [18F]beta-CFT, is reduced in early Parkinson's disease. **1999**, 31, 119-24		42
1285	Comparison of FORE, OSEM and SAGE algorithms to 3DRP in 3D PET using phantom and human subject data. **1999**, 46, 1114-1120		10
1284	Access www.neurology.org now for full-text articles. **2000**, 55, 209		
1283	Dopamine D(2) receptor quantification in extrastriatal brain regions using [(123)I]epidepride with bolus/infusion. **2000**, 36, 322-9		17
1282	In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. **2000**, 47, 493-503		443
1281	Quantitation of striatal and extrastriatal D-2 dopamine receptors using PET imaging of [(18)F]fallypride in nonhuman primates. **2000**, 38, 71-9		64

1280	In vivo PET studies of the dopamine D2 receptors in rhesus monkeys with long-term MPTP-induced parkinsonism. **2000**, 38, 105-13		41
1279	Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: validation and reproducibility. *Journal of Cerebral Blood Flow and Metabolism*, **2000**, 20, 225-43	7.3	128
1278	Analysis of four dopaminergic tracers kinetics using two different tissue input function methods. *Journal of Cerebral Blood Flow and Metabolism*, **2000**, 20, 653-60	7.3	19
1277	Modeling dynamic PET-SPECT studies in the wavelet domain. *Journal of Cerebral Blood Flow and Metabolism*, **2000**, 20, 879-93	7.3	50
1276	Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. **2000**, 23, 326-34		98
1275	Measurement of extrastriatal D2-like receptor binding with [11C]FLB 457--a test-retest analysis. **2000**, 27, 1666-73		44
1274	Simplified quantification of dopamine transporters in humans using [99mTc]TRODAT-1 and single-photon emission tomography. **2000**, 27, 1714-8		28
1273	PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. **2000**, 55, 205-9		62
1272	Access www.neurology.org now for full-text articles. **2000**, 54, 2251		
1271	[11 C]Flumazenil binding in the medial temporal lobe in patients with temporal lobe epilepsy: correlation with hippocampal MR volumetry, T2 relaxometry, and neuropathology. **2000**, 54, 2252-60		53
1270	Derivation of [(11)C]WAY-100635 binding parameters with reference tissue models: effect of violations of model assumptions. **2000**, 27, 487-92		56
1269	Graphical analysis of PET data applied to reversible and irreversible tracers. **2000**, 27, 661-70		303
1268	PET physiological measurements using constant infusion. **2000**, 27, 657-60		73
1267	The role of model-based methods in the development of single scan techniques. **2000**, 27, 637-42		17
1266	D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. **2001**, 11, 105-10		112
1265	Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. **2001**, 293, 1164-6		732
1264	Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. **2001**, 28, 595-608		162
1263	Regional mu opioid receptor regulation of sensory and affective dimensions of pain. **2001**, 293, 311-5		668

1262	Physiological Modelling of Positron Emission Tomography Images. **2001**, 179-211		2
1261	Analyses of [(18)F]altanserin bolus injection PET data. II: consideration of radiolabeled metabolites in humans. **2001**, 41, 11-21		47
1260	Effect of endogenous dopamine on extrastriatal [□□C]FLB 457 binding measured by PET. **2001**, 41, 87-95		55
1259	Age-related changes of dopamine D1-like and D2-like receptor binding in the F344/N rat striatum revealed by positron emission tomography and in vitro receptor autoradiography. **2001**, 41, 285-93		45
1258	Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. **2001**, 49, 298-303		179
1257	Modeling of receptor ligand data in PET and SPECT imaging: a review of major approaches. **2001**, 11, 30-9		25
1256	A strategy for removing the bias in the graphical analysis method. *Journal of Cerebral Blood Flow and Metabolism*, **2001**, 21, 307-20	7.3	133
1255	A reversible tracer analysis approach to the study of effective dopamine turnover. *Journal of Cerebral Blood Flow and Metabolism*, **2001**, 21, 469-76	7.3	57
1254	Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. *Journal of Cerebral Blood Flow and Metabolism*, **2001**, 21, 1034-57	7.3	458
1253	Measurement of cortical dopamine d1 receptor binding with 11C[SCH23390]: a test-retest analysis. *Journal of Cerebral Blood Flow and Metabolism*, **2001**, 21, 1146-50	7.3	26
1252	Apomorphine-induced changes in synaptic dopamine levels: positron emission tomography evidence for presynaptic inhibition. *Journal of Cerebral Blood Flow and Metabolism*, **2001**, 21, 1151-9	7.3	46
1251	Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. **2001**, 25, 476-88		59
1250	mu-Opioid receptors and limbic responses to aversive emotional stimuli. **2002**, 99, 7084-9		73
1249	Fast formation of statistically reliable FDG parametric images based on clustering and principal components. **2002**, 47, 455-68		53
1248	Positron emission tomography shows reduced striatal dopamine D1 but not D2 receptors in juvenile neuronal ceroid lipofuscinosis. **2002**, 33, 138-41		17
1247	Bilateral human fetal striatal transplantation in Huntington's disease. **2002**, 58, 687-95		208
1246	Human [/sup 123/I]5-I-A-85380 dynamic SPECT studies in normals: kinetic analysis and parametric imaging.		
1245	Serotonin transporter binding in patients with mood disorders: a PET study with [11C](+)McN5652. **2002**, 51, 715-22		132

1244	Age-related decline of serotonin transporters in living human brain of healthy males. **2002**, 71, 751-7		68
1243	Monitoring the correction of glycogen storage disease type 1a in a mouse model using [(18)F]FDG and a dedicated animal scanner. **2002**, 71, 1293-301		9
1242	Improved parametric image generation using spatial-temporal analysis of dynamic PET studies. **2002**, 15, 697-707		47
1241	Wavelet-aided parametric mapping of cerebral dopamine D2 receptors using the high affinity PET radioligand [11C]FLB 457. **2002**, 17, 47-60		49
1240	Abstracts. **2002**, 16, S1-S108		
1239	Positron emission tomography: imaging and quantification of neurotransporter availability. **2002**, 27, 287-99		83
1238	Cerebral uptake of [ethyl-11C]vinpocetine and 1-[11C]ethanol in cynomolgous monkeys: a comparative preclinical PET study. **2002**, 29, 753-9		12
1237	Dopamine release in human ventral striatum and expectation of reward. **2002**, 136, 359-63		275
1236	mu-opioid receptor-mediated antinociceptive responses differ in men and women. **2002**, 22, 5100-7		297
1235	The impact of prenatal stress, fetal alcohol exposure, or both on development: perspectives from a primate model. **2002**, 27, 285-98		160
1234	Quantification of [(123)I]PE2I binding to dopamine transporters with SPET. **2002**, 29, 623-31		13
1233	Quantification of dopamine transporters in the mouse brain using ultra-high resolution single-photon emission tomography. **2002**, 29, 691-8		76
1232	PET studies on the brain uptake and regional distribution of [11C]vinpocetine in human subjects. **2002**, 106, 325-32		45
1231	In vivo PET studies of the dopamine D1 receptors in rhesus monkeys with long-term MPTP-induced Parkinsonism. **2002**, 44, 111-5		11
1230	Density and affinity of the dopamine D2 receptors in aged symptomatic and asymptomatic MPTP-treated monkeys: PET studies with [11C]raclopride. **2002**, 44, 198-202		34
1229	Mu-receptor agonism with alfentanil increases striatal dopamine D2 receptor binding in man. **2002**, 45, 25-30		49
1228	Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. **2002**, 46, 170-88		223
1227	Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data. *Journal of Cerebral Blood Flow and Metabolism*, **2002**, 22, 232-9	7.3	101

1226	Quantitative analysis for estimating binding potential of the brain serotonin transporter with [11 C]McN5652. *Journal of Cerebral Blood Flow and Metabolism*, **2002**, 22, 490-501	7.3	35
1225	In vivo receptor assay with multiple ligand concentrations: an equilibrium approach. *Journal of Cerebral Blood Flow and Metabolism*, **2002**, 22, 1132-41	7.3	32
1224	Positron emission tomography compartmental models: a basis pursuit strategy for kinetic modeling. *Journal of Cerebral Blood Flow and Metabolism*, **2002**, 22, 1425-39	7.3	148
1223	Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer's disease. **2003**, 17, 567-73		63
1222	Quantification of human brain benzodiazepine receptors using [18F]fluoroethylflumazenil: a first report in volunteers and epileptic patients. **2003**, 30, 1630-6		12
1221	Chronic subthalamic nucleus stimulation and striatal D2 dopamine receptors in Parkinson's disease--A [(11)C]-raclopride PET study. **2003**, 250, 1219-23		44
1220	Deep brain stimulation of the subthalamic nucleus does not increase the striatal dopamine concentration in parkinsonian humans. **2003**, 18, 41-8		128
1219	Positron emission tomography (PET) advances in neurological applications. **2003**, 510, 107-115		1
1218	Age and severity of nigrostriatal damage at onset of Parkinson's disease. **2003**, 47, 152-8		32
1217	Graphical analysis of 2-[18F]FA binding to nicotinic acetylcholine receptors in rhesus monkey brain. **2003**, 48, 25-34		76
1216	VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET. **2003**, 49, 20-8		61
1215	No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET. **2003**, 48, 184-8		157
1214	In vivo measurement of receptor density and affinity: comparison of the routine sequential method with a nonsequential method in studies of dopamine D2 receptors with [11C]raclopride. *Journal of Cerebral Blood Flow and Metabolism*, **2003**, 23, 280-4	7.3	9
1213	Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. *Journal of Cerebral Blood Flow and Metabolism*, **2003**, 23, 1096-112	7.3	502
1212	Sequential versus nonsequential measurement of density and affinity of dopamine D2 receptors with [11C]raclopride: effect of methamphetamine. *Journal of Cerebral Blood Flow and Metabolism*, **2003**, 23, 1489-94	7.3	17
1211	Principles of tracer kinetic analysis. **2003**, 13, 689-704		12
1210	Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model. **2003**, 18, 975-89		104
1209	Presymptomatic diagnosis of experimental Parkinsonism with 123I-PE2I SPECT. **2003**, 19, 810-6		36

1208	Raclopride studies of dopamine release: dependence on presynaptic integrity. **2003**, 54, 1193-9	21
1207	Striatal dopamine D1 and D2 receptors in burning mouth syndrome. **2003**, 101, 149-54	186
1206	Altered dopamine D2 receptor binding in atypical facial pain. **2003**, 106, 43-8	152
1205	Quantification of brain mu-opioid receptors with [11C]carfentanil: reference-tissue methods. **2003**, 30, 177-86	56
1204	Small animal imaging with high resolution single photon emission tomography. **2003**, 30, 889-95	84
1203	A review of graphical methods for tracer studies and strategies to reduce bias. **2003**, 30, 833-44	67
1202	The use of gene-manipulated mice in the validation of receptor binding radiotracer. **2003**, 30, 851-60	17
1201	A linear wavelet filter for parametric imaging with dynamic PET. **2003**, 22, 289-301	56
1200	Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. **2003**, 60, 1145-53	293
1199	[11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease. **2003**, 126, 2648-55	57
1198	A noninvasive LSO-APD blood radioactivity monitor for PET imaging studies. **2003**, 50, 1457-1461	3
1197	Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. **2003**, 28, 2000-9	206
1196	Rank-shaping regularization of exponential spectral analysis for application to functional parametric mapping. **2003**, 48, 3819-41	33
1195	High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. **2003**, 60, 386-91	104
1194	Kinetic Modeling in Positron Emission Tomography. **2004**, 499-540	44
1193	Positron emission tomography receptor assay with multiple ligand concentrations: an equilibrium approach. **2004**, 385, 169-84	4
1192	Imaging dopamine receptors in the rat striatum with the MicroPET R4: kinetic analysis of [11C]raclopride binding using graphical methods. **2004**, 385, 213-28	5
1191	Quantitative analysis of dopamine D2 receptor kinetics with small animal positron emission tomography. **2004**, 385, 228-39	3

1190	Impact of motion correction on parametric images in PET neuroreceptor studies.		
1189	Risperidone is effective for wandering and disturbed sleep/wake patterns in Alzheimer's disease. **2004**, 17, 61-7		41
1188	Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. **2004**, 61, 1271-9		235
1187	Effect of normalization method on image uniformity and binding potential estimates on microPET.		2
1186	Decreased brain dopaminergic transporters in HIV-associated dementia patients. **2004**, 127, 2452-8		172
1185	.		
1184	Limbic reductions of 5-HT1A receptor binding in human temporal lobe epilepsy. **2004**, 62, 1343-51		147
1183	Evaluation of 5-(2-(4-pyridinyl)vinyl)-6-chloro-3-(1-methyl-2-(S)-pyrrolidinylmethoxy)pyridine and its analogues as PET radioligands for imaging nicotinic acetylcholine receptors. **2004**, 91, 600-12		16
1182	DRD2 gene transfer into the nucleus accumbens core of the alcohol preferring and nonpreferring rats attenuates alcohol drinking. **2004**, 28, 720-8		90
1181	Measuring the in vivo binding parameters of [18F]-fallypride in monkeys using a PET multiple-injection protocol. *Journal of Cerebral Blood Flow and Metabolism*, **2004**, 24, 309-22	7.3	47
1180	Prenatal stress, moderate fetal alcohol, and dopamine system function in rhesus monkeys. **2004**, 26, 169-78		43
1179	Striatal dopaminergic system in dopa-responsive dystonia: a multi-tracer PET study shows increased D2 receptors. **2004**, 111, 59-67		30
1178	Evaluation of the use of a standard input function for compartment analysis of [123I]iomazenil data: factors influencing the quantitative results. **2004**, 18, 563-72		5
1177	In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates. **2004**, 175, 274-86		54
1176	Non-invasive assessment of distribution volume ratios and binding potential: tissue heterogeneity and interindividually averaged time-activity curves. **2004**, 31, 564-77		8
1175	MDMA-evoked changes in [11C]raclopride and [11C]NMSP binding in living pig brain. **2004**, 53, 222-33		34
1174	Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. **2004**, 55, 306-19		3088
1173	PET Measurement of rCBF in the presence of a neurochemical tracer. **2004**, 132, 199-208		12

1172	Fully 4D dynamic image reconstruction by nonlinear constrained programming.	
1171	Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. **2004**, 127, 2747-54	307
1170	Gradients of dopamine D1- and D2/3-binding sites in the basal ganglia of pig and monkey measured by PET. **2004**, 22, 1076-1076	
1169	Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia. **2004**,	
1168	[123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Delta9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients. **2004**, 55, 904-15	43
1167	Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia. **2004**, 71, 371-5	33
1166	PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of Parkinson's disease. **2004**, 189, 361-8	41
1165	Sensitivity of [11C]N-methylpyrrolidinyl benzilate ([11C]NMPYB) to endogenous acetylcholine: PET imaging vs tissue sampling methods. **2004**, 31, 393-7	12
1164	Simplified PET measurement for evaluating histamine H1 receptors in human brains using [11C]doxepin. **2004**, 31, 1005-11	18
1163	Bootstrapped DEPICT for error estimation in PET functional imaging. **2004**, 21, 1096-104	10
1162	Gradients of dopamine D1- and D2/3-binding sites in the basal ganglia of pig and monkey measured by PET. **2004**, 22, 1076-83	25
1161	Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. **2004**, 161, 826-35	399
1160	Limitations of bi-linear regression analysis for the determination of receptor occupancy with positron emission tomography. **2004**, 25, 451-9	5
1159	Effects of metabolite correction for arterial input function on quantitative receptor images with 11C-flumazenil in clinical positron emission tomography studies. **2004**, 28, 428-35	15
1158	Quantitative Functional Imaging with Positron Emission Tomography: Principles and Instrumentation. **2005**, 57-116	1
1157	PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. **2005**, 128, 2777-85	208
1156	MicroPET/sup /spl reg// R4 neuro-imaging in rats and post-mortem measures.	
1155	In-vivo PET imaging of inducible D2R reporter transgene expression using [11C]FLB 457 as reporter probe in living rats. **2005**, 26, 259-68	12

1154	Development of a simultaneous PET/microdialysis method to identify the optimal dose of 11C-raclopride for small animal imaging. **2005**, 144, 25-34		35
1153	Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. *Journal of Cerebral Blood Flow and Metabolism*, **2005**, 25, 1528-47	7.3	566
1152	Dopamine D(2) receptor availability is associated with subjective responses to alcohol. **2005**, 29, 965-70		60
1151	Moderate-level prenatal alcohol exposure alters striatal dopamine system function in rhesus monkeys. **2005**, 29, 1685-97		40
1150	A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian). **2005**, 180, 377-84		81
1149	Analysis of neuroreceptor PET-data based on cytoarchitectonic maximum probability maps: a feasibility study. **2005**, 210, 447-53		9
1148	Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia. **2005**, 210, 519-23		35
1147	Micropet imaging: in vivo biochemistry in small animals. **2005**, 112, 319-30		38
1146	Use of reference tissue models for quantification of histamine H1 receptors in human brain by using positron emission tomography and [11c]doxepin. **2005**, 19, 425-33		16
1145	An internet-based "kinetic imaging system" (KIS) for MicroPET. **2005**, 7, 330-41		40
1144	Interaction between LSD and dopamine D2/3 binding sites in pig brain. **2005**, 56, 198-204		18
1143	ntPET: A New Application of PET Imaging for Characterizing the Kinetics of Endogenous Neurotransmitter Release. **2005**, 4, 7290.2005.05130		45
1142	A new mutation of the tau gene, G303V, in early-onset familial progressive supranuclear palsy. **2005**, 62, 1444-50		81
1141	Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study. **2005**, 103, 968-73		34
1140	Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. **2005**, 25, 7754-62		607
1139	Kinetic modeling of PET data without blood sampling. **2005**, 52, 697-702		14
1138	Tracer Kinetic Modeling in PET. **2005**, 127-159		48
1137	Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3, and 6. **2005**, 62, 1280-5		81

1136	Regional reductions in serotonin 1A receptor binding in juvenile myoclonic epilepsy. **2005**, 62, 946-50	56
1135	The influence of measurement uncertainties on the evaluation of the distribution volume ratio and binding potential in rat studies on a microPET R4: a phantom study. **2005**, 50, 2859-69	10
1134	Wavelet variance components in image space for spatiotemporal neuroimaging data. **2005**, 25, 159-68	16
1133	Omission of serial arterial blood sampling in neuroreceptor imaging with independent component analysis. **2005**, 26, 885-90	28
1132	Positron Emission Tomography. **2005**,	209
1131	Behavioral response to novelty correlates with dopamine receptor availability in striatum of Göttingen minipigs. **2005**, 164, 172-7	22
1130	Mapping the amphetamine-evoked dopamine release in the brain of the Göttingen minipig. **2005**, 65, 1-9	26
1129	The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects. **2005**, 57, 640-6	45
1128	Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. **2005**, 57, 1573-82	138
1127	Effects of tryptophan depletion on the serotonin transporter in healthy humans. **2005**, 58, 825-30	89
1126	[11C]vinpocetine: a prospective peripheral benzodiazepine receptor ligand for primate PET studies. **2005**, 229-230, 219-23	37
1125	Neuroreceptor imaging in psychiatry: theory and applications. **2005**, 67, 385-440	13
1124	Handbook of Biomedical Image Analysis. **2005**,	13
1123	MAP-based kinetic analysis for voxel-by-voxel compartment model estimation: detailed imaging of the cerebral glucose metabolism using FDG. **2006**, 29, 1203-11	10
1122	Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: a multi-tracer PET study. **2006**, 30, 26-35	46
1121	High opiate receptor binding potential in the human lateral pain system. **2006**, 30, 692-9	120
1120	A comparison of recent parametric neuroreceptor mapping approaches based on measurements with the high affinity PET radioligands [11C]FLB 457 and [11C]WAY 100635. **2006**, 32, 1690-708	63
1119	Multi-resolution Bayesian regression in PET dynamic studies using wavelets. **2006**, 32, 111-21	36

1118	A1 adenosine receptor PET using [18F]CPFPX: displacement studies in humans. **2006**, 32, 1100-5		17
1117	Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. **2006**, 33, 94-102		105
1116	An extended simplified reference tissue model for the quantification of dynamic PET with amphetamine challenge. **2006**, 33, 550-63		37
1115	Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. **2006**, 59, 821-8		99
1114	D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. **2006**, 85, 232-44		116
1113	Belief or Need? Accounting for individual variations in the neurochemistry of the placebo effect. **2006**, 20, 15-26		83
1112	. **2006**,		1
1111	Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. **2006**, 63, 1199-208		220
1110	Quantitative autoradiography of ligands for dopamine receptors and transporters in brain of GEttingen minipig: comparison with results in vivo. **2006**, 59, 211-9		24
1109	Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. **2006**, 59, 243-51		92
1108	Inhibition of [11C]mirtazapine binding by alpha2-adrenoceptor antagonists studied by positron emission tomography in living porcine brain. **2006**, 59, 463-71		20
1107	Imaging triiodothyronine binding kinetics in rat brain: a model for studies in human subjects. **2006**, 60, 212-22		8
1106	Sequential versus nonsequential measurement of density and affinity of dopamine D2 receptors with [11C]raclopride: 2: effects of DAT inhibitors. *Journal of Cerebral Blood Flow and Metabolism*, **2006**, 26, 28-37	7.3	2
1105	Serial microPET measures of the metabolic reaction to a microdialysis probe implant. **2006**, 155, 272-84		135
1104	[(11)C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor. **2006**, 113, 187-93		35
1103	Imaging of serotonin transporters and its blockade by citalopram in patients with major depression using a novel SPECT ligand [123I]-ADAM. **2006**, 113, 659-70		57
1102	Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2. **2006**, 188, 119-27		68
1101	Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. **2007**, 190, 241-9		42

1100	Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies. **2006**, 21, 970-5	12
1099	Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. **2006**, 59, 512-9	1009
1098	In Vivo Radiotracer Imaging. 103-147	
1097	Comparison between the ROI based and pixel based analysis for neuroreceptor studies performed on the high resolution research tomograph (HRRT). **2006**,	
1096	Temporal resolution of ntPET using either arterial or reference region-derived plasma input functions. **2006**, 2006, 2005-8	7
1095	Autosomal dominant dystonia-plus with cerebral calcifications. **2006**, 67, 620-5	31
1094	Quantitative imaging with the micro-PET small-animal PET tomograph. **2006**, 73, 191-218	14
1093	Visualizing pathology deposits in the living brain of patients with Alzheimer's disease. **2006**, 412, 144-60	34
1092	The quest for Eldorado: development of radioligands for in vivo imaging of nicotinic acetylcholine receptors in human brain. **2006**, 12, 3877-900	52
1091	Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. **2006**, 26, 5777-85	234
1090	Variations in the human pain stress experience mediated by ventral and dorsal basal ganglia dopamine activity. **2006**, 26, 10789-95	226
1089	PET of brain amyloid and tau in mild cognitive impairment. **2006**, 355, 2652-63	573
1088	Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. **2006**, 129, 2017-28	193
1087	Increased occupancy of dopamine receptors in human striatum during cue-elicited cocaine craving. **2006**, 31, 2716-27	244
1086	Concepts of registration and correction of head motion in positron emission tomography. **2006**, 16, 67-74	12
1085	Serotonin 1A receptors in the living brain of Alzheimer's disease patients. **2006**, 103, 702-7	196
1084	[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. **2006**, 67, 446-52	893
1083	Decreased central mu-opioid receptor availability in fibromyalgia. **2007**, 27, 10000-6	373

1082	Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans. **2007**, 32, 450-7	105
1081	Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. **2007**, 27, 10957-68	246
1080	11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. **2007**, 68, 1205-12	300
1079	Methods for Parkinson's rat model PET image analysis with regions of interest. **2007**,	2
1078	5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB. **2007**, 164, 1858-65	62
1077	Movement correction of [18F]FDDNP PET studies for brain amyloid imaging. **2007**,	1
1076	A scatter-corrected list-mode reconstruction and a practical scatter/random approximation technique for dynamic PET imaging. **2007**, 52, 2089-106	12
1075	Placebo effects on human mu-opioid activity during pain. **2007**, 104, 11056-61	442
1074	Imaging beta-amyloid burden in aging and dementia. **2007**, 68, 1718-25	883
1073	Sleep deprivation increases A1 adenosine receptor binding in the human brain: a positron emission tomography study. **2007**, 27, 2410-5	141
1072	Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. **2007**, 27, 6174-84	313
1071	Comparison of simplified methods for quantitative analysis of [18F]FDDNP PET data. **2007**,	1
1070	Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats. **2007**, 48, 1147-53	53
1069	Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. **2007**, 48, 547-52	172
1068	Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. **2007**, 64, 431-4	297
1067	PET imaging of dopamine D2 receptor and transporter availability during acquisition of cocaine self-administration in rhesus monkeys. **2007**, 1, 33-9	16
1066	Impact of accurate motion-corrected statistical reconstruction on dynamic PET kinetic parameter estimation. **2007**,	1
1065	Effect of aging on cerebral A1 adenosine receptors: A [18F]CPFPX PET study in humans. **2007**, 28, 1914-24	51

1064	Individual differences in reward responding explain placebo-induced expectations and effects. **2007**, 55, 325-36	354
1063	Simplifications in analyzing positron emission tomography data: effects on outcome measures. **2007**, 34, 743-56	9
1062	Quantification of alpha4beta2* nicotinic receptors in the rat brain with microPET and 2-[18F]F-A-85380. **2007**, 34, 1352-62	19
1061	Mapping the amphetamine-evoked changes in [11C]raclopride binding in living rat using small animal PET: modulation by MAO-inhibition. **2007**, 35, 38-46	30
1060	A systematic comparison of kinetic modelling methods generating parametric maps for [(11)C]-(R)-PK11195. **2007**, 36, 28-37	33
1059	Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease. **2007**, 36, 298-312	75
1058	Fast and reliable estimation of multiple parametric images using an integrated method for dynamic SPECT. **2007**, 26, 179-89	9
1057	Effect of measurement uncertainty on region of interest based and parametric binding potential estimates for the high resolution research tomograph (HRRT). **2007**,	
1056	Cutting-edge brain imaging with positron emission tomography. **2007**, 17, 427-40, viii	6
1055	Cutting-Edge Brain Imaging with Positron Emission Tomography. **2007**, 2, 91-104	3
1054	Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. **2007**, 61, 101-10	80
1053	Altered central micro-opioid receptor binding after psychological trauma. **2007**, 61, 1030-8	93
1052	Novel 5-HTTLPR allele associates with higher serotonin transporter binding in putamen: a [(11)C] DASB positron emission tomography study. **2007**, 62, 327-31	175
1051	High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. **2007**, 62, 878-83	101
1050	Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. **2007**, 62, 229-34	420
1049	Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. **2007**, 62, 468-74	106
1048	Time-course of change in [11C]carfentanil and [11C]raclopride binding potential after a nonpharmacological challenge. **2007**, 61, 707-14	51
1047	Seeing what Alzheimer saw. **2007**, 13, 129-31	8

1046	Positron emission tomography displacement sensitivity: predicting binding potential change for positron emission tomography tracers based on their kinetic characteristics. *Journal of Cerebral Blood Flow and Metabolism*, **2007**, 27, 606-17	7.3	41
1045	Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. *Journal of Cerebral Blood Flow and Metabolism*, **2007**, 27, 857-71	7.3	83
1044	Quantification of dopamine transporter binding using [18F]FP-beta-CIT and positron emission tomography. *Journal of Cerebral Blood Flow and Metabolism*, **2007**, 27, 1397-406	7.3	31
1043	In vivo measurement of density and affinity of the monoamine vesicular transporter in a unilateral 6-hydroxydopamine rat model of PD. *Journal of Cerebral Blood Flow and Metabolism*, **2007**, 27, 1407-15	7.3	39
1042	Evaluation of methods for generating parametric (R-[11C]PK11195 binding images. *Journal of Cerebral Blood Flow and Metabolism*, **2007**, 27, 1603-15	7.3	28
1041	Evaluation of four pyridine analogs to characterize 6-OHDA-induced modulation of mGluR5 function in rat brain using microPET studies. *Journal of Cerebral Blood Flow and Metabolism*, **2007**, 27, 1623-31	7.3	15
1040	Consensus nomenclature for in vivo imaging of reversibly binding radioligands. *Journal of Cerebral Blood Flow and Metabolism*, **2007**, 27, 1533-9	7.3	1597
1039	The 8th International Conference on Quantification of Brain Function with PET. *Journal of Cerebral Blood Flow and Metabolism*, **2007**, 27, PP01-04M-PP10-08U	7.3	
1038	Heterogeneous effects of alcohol on dopamine release in the striatum: a PET study. **2007**, 31, 965-73		62
1037	Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. **2007**, 14, 523-8		161
1036	Reduced midbrain-pons serotonin transporter binding in patients with obsessive-compulsive disorder. **2007**, 115, 388-94		29
1035	The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies. **2007**, 113, 1-15		137
1034	PET kinetic analysis --pitfalls and a solution for the Logan plot. **2007**, 21, 1-8		31
1033	Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography. **2007**, 193, 539-45		46
1032	Test-retest stability of cerebral A1 adenosine receptor quantification using [18F]CPFPX and PET. **2007**, 34, 1061-70		17
1031	The lack of expression of the peripheral benzodiazepine receptor characterises microglial response in anaplastic astrocytomas. **2007**, 85, 95-103		23
1030	Voxel-based NK1 receptor occupancy measurements with [(18)F]SPA-RQ and positron emission tomography: a procedure for assessing errors from image reconstruction and physiological modeling. **2007**, 9, 284-94		5
1029	Distribution volume as an alternative to the binding potential for sigma1 receptor imaging. **2007**, 21, 533-5		16

1028	Initial comparison of ntPET with microdialysis measurements of methamphetamine-induced dopamine release in rats: support for estimation of dopamine curves from PET data. **2008**, 10, 67-73	16
1027	Cerebral glucose metabolism and D2/D3 receptor availability in young adults with cannabis dependence measured with positron emission tomography. **2008**, 197, 549-56	62
1026	Neuroimaging of mirtazapine enantiomers in humans. **2008**, 200, 273-9	3
1025	Brain mu-opioid receptor binding: relationship to relapse to cocaine use after monitored abstinence. **2008**, 200, 475-86	52
1024	Cerebral A1 adenosine receptors (A1AR) in liver cirrhosis. **2008**, 35, 589-97	27
1023	The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias. **2008**, 38, 1-15	81
1022	PET kinetic analysis: error consideration of quantitative analysis in dynamic studies. **2008**, 22, 1-11	21
1021	Cancer and blood concentrations of the comutagen harmane in essential tremor. **2008**, 23, 1747-51	6
1020	Subthalamotomy in cervical dystonia: A case study of lesion location and clinical outcome. **2008**, 23, 1751-6	8
1019	Intact presupplementary motor area function in early, untreated Parkinson's disease. **2008**, 23, 1756-9	4
1018	Reversal of head drop after discontinuation of olanzapine in a DLB patient. **2008**, 23, 1760-2	5
1017	Hemidystonia secondary to thalamic hemorrhage treated with GPi stimulation. **2008**, 23, 1762-6	13
1016	Autonomic dysfunction in different subtypes of multiple system atrophy. **2008**, 23, 1766-72	30
1015	Ultrasonographic findings of shoulder disorders in patients with Parkinson's disease. **2008**, 23, 1772-6	15
1014	Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. **2008**, 23, 1776-80	130
1013	Psychosis, short stature in benign hereditary chorea: a novel thyroid transcription factor-1 mutation. **2008**, 23, 1744-7	39
1012	Arm swing is reduced in idiopathic cervical dystonia. **2008**, 23, 1784-7	18
1011	What relation is there between deep brain stimulation and coping strategies in Parkinson's disease?. **2008**, 23, 1780-4	11

1010	Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. **2008**, 63, 388-94		60
1009	Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. **2008**, 64, 388-401		363
1008	Comparison of noninvasive quantification methods of in vivo vesicular acetylcholine transporter using [123I]-IBVM SPECT imaging. *Journal of Cerebral Blood Flow and Metabolism*, **2008**, 28, 1624-34	7.3	16
1007	Multiple linear analysis methods for the quantification of irreversibly binding radiotracers. *Journal of Cerebral Blood Flow and Metabolism*, **2008**, 28, 1965-77	7.3	10
1006	Noninvasive estimation of normalized distribution volume: application to the muscarinic-2 ligand [(18)F]FP-TZTP. *Journal of Cerebral Blood Flow and Metabolism*, **2008**, 28, 420-30	7.3	17
1005	Improving PET receptor binding estimates from Logan plots using principal component analysis. *Journal of Cerebral Blood Flow and Metabolism*, **2008**, 28, 852-65	7.3	30
1004	Sensory processing disorder in a primate model: evidence from a longitudinal study of prenatal alcohol and prenatal stress effects. **2008**, 79, 100-13		42
1003	Functional neuroimaging in multiple sclerosis with radiolabelled glia markers: preliminary comparative PET studies with [11C]vinpocetine and [11C]PK11195 in patients. **2008**, 264, 9-17		62
1002	What were they thinking? Cognitive states may influence [11C]raclopride binding potential in the striatum. **2008**, 430, 38-42		17
1001	Midbrain serotonin and striatum dopamine transporter binding in double depression: a one-year follow-up study. **2008**, 441, 291-5		35
1000	Validation of the reference tissue model for estimation of dopaminergic D2-like receptor binding with [18F](N-methyl)benperidol in humans. **2008**, 35, 335-41		10
999	Changes in midbrain serotonin transporter availability in atypically depressed subjects after one year of psychotherapy. **2008**, 32, 229-37		47
998	Estimating neurotransmitter kinetics with ntPET: a simulation study of temporal precision and effects of biased data. **2008**, 39, 1162-79		16
997	Robust estimation of the arterial input function for Logan plots using an intersectional searching algorithm and clustering in positron emission tomography for neuroreceptor imaging. **2008**, 40, 26-34		16
996	Associations between dopamine D2-receptor binding and cognitive performance indicate functional compartmentalization of the human striatum. **2008**, 40, 1287-95		56
995	Measurement of GABAA receptor binding in vivo with [11C]flumazenil: a test-retest study in healthy subjects. **2008**, 41, 260-9		34
994	Automated system for parametric image analysis in neuroreceptor binding studies with PET. **2008**, 41, T77		
993	Simplified parametric methods for [11C]PIB studies. **2008**, 42, 76-86		79

992	Kinetic analyses of [123I]IBZM SPECT for quantification of striatal dopamine D2 receptor binding: a critical evaluation of the single-scan approach. **2008**, 42, 548-58	15
991	Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. **2008**, 65, 220-31	459
990	Automated (11)C-PiB standardized uptake value ratio. **2008**, 15, 1376-89	17
989	Discovery of (-)-7-methyl-2-exo-[3'-(6-[18F]fluoropyridin-2-yl)-5'-pyridinyl]-7-azabicyclo[2.2.1]heptane, a radiolabeled antagonist for cerebral nicotinic acetylcholine receptor (alpha4beta2-nAChR) with optimal positron emission tomography imaging properties. **2008**, 51, 4751-64	28
988	Prenatal Stress Influences on Neurobehavior, Stress Reactivity, and Dopaminergic Function in Rhesus Macaques. **2008**, 231-258	4
987	Voxel-based analysis of 11C-PIB scans for diagnosing Alzheimer's disease. **2008**, 49, 1262-9	37
986	Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. **2008**, 28, 10422-33	203
985	Seasonal variation in human brain serotonin transporter binding. **2008**, 65, 1072-8	195
984	Sleep deprivation decreases binding of [11C]raclopride to dopamine D2/D3 receptors in the human brain. **2008**, 28, 8454-61	148
983	Comparison of 3D-OP-OSEM and 3D-FBP reconstruction algorithms for High-Resolution Research Tomograph studies: effects of randoms estimation methods. **2008**, 53, 3217-30	28
982	Imaging of opioid receptors in the central nervous system. **2008**, 131, 1171-96	149
981	Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. **2008**, 33, 1239-51	200
980	Monoamine oxidase A genotype predicts human serotonin 1A receptor availability in vivo. **2008**, 28, 11354-9	40
979	Effects of cocaine and MDMA self-administration on serotonin transporter availability in monkeys. **2008**, 33, 219-25	43
978	Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. **2008**, 33, 653-65	109
977	Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlate with reward-related ventral striatal dopamine release. **2008**, 28, 14311-9	376
976	Compartmental modeling of 11C-HOMADAM binding to the serotonin transporter in the healthy human brain. **2008**, 49, 2018-25	24
975	Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. **2008**, 131, 1630-45	714

974	PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. **2008**, 26, 378-83	84
973	Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. **2008**, 65, 113-20	158
972	Imaging amyloid deposition in Lewy body diseases. **2008**, 71, 903-10	376
971	Estimation from PET data of transient changes in dopamine concentration induced by alcohol: support for a non-parametric signal estimation method. **2008**, 53, 1353-67	9
970	Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. **2008**, 71, 1790-5	95
969	Revisiting an old issue: the discrepancy between tissue ratio-derived binding parameters and kinetic modeling-derived parameters after a bolus of the serotonin transporter radioligand 123I-ADAM. **2008**, 49, 176-8	14
968	Opioid receptor PET reveals the psychobiologic correlates of reward processing. **2008**, 49, 1257-61	43
967	Impact of wavelet based denoising of [11C](R)-PK11195 time activity curves on accuracy and precision of kinetic analysis. **2008**, 35, 5069-78	1
966	. **2008**,	
965	Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. **2008**, 65, 1467-71	163
964	Black cohosh has central opioid activity in postmenopausal women: evidence from naloxone blockade and positron emission tomography neuroimaging. **2008**, 15, 832-40	41
963	Timing of moderate level prenatal alcohol exposure influences gene expression of sensory processing behavior in rhesus monkeys. **2009**, 3, 30	8
962	Evaluation of two graphical approaches for regional analysis and parametric mapping of dynamic [18F]FDDNP PET studies. **2009**,	
961	Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. **2009**, 50, 348-55	89
960	11C-PK11195 PET for the in vivo evaluation of neuroinflammation in the rat brain after cortical spreading depression. **2009**, 50, 1904-11	30
959	Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. **2009**, 29, 1860-73	2076
958	HRRT versus HR+ human brain PET studies: an interscanner test-retest study. **2009**, 50, 693-702	51
957	Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. **2009**, 66, 1476-81	247

956	Cerebral histamine H1 receptor binding potential measured with PET under a test dose of olopatadine, an antihistamine, is reduced after repeated administration of olopatadine. **2009**, 50, 887-92	11
955	Using cerebral white matter for estimation of nondisplaceable binding of 5-HT1A receptors in temporal lobe epilepsy. **2009**, 50, 1794-800	10
954	Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. **2009**, 66, 81-7	52
953	PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. **2009**, 72, 1211-6	92
952	Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. **2009**, 132, 1310-23	526
951	Dopamine transporters in striatum correlate with deactivation in the default mode network during visuospatial attention. **2009**, 4, e6102	114
950	Reduced ventrolateral fMRI response during observation of emotional gestures related to the degree of dopaminergic impairment in Parkinson disease. **2009**, 21, 1321-31	41
949	High occupancy of sigma1 receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [11C]SA4503. **2009**, 12, 1127-31	53
948	Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. **2009**, 132, 2970-9	185
947	Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. **2009**, 66, 1469-75	350
946	Characterization of PiB binding to white matter in Alzheimer disease and other dementias. **2009**, 50, 198-204	76
945	Cognition, reserve, and amyloid deposition in normal aging. **2010**, 67, 353-64	246
944	Evidence for modulation of opioidergic activity in central vestibular processing: A [(18)F] diprenorphine PET study. **2010**, 31, 550-5	14
943	Dose dependency of brain histamine H(1) receptor occupancy following oral administration of cetirizine hydrochloride measured using PET with [11C]doxepin. **2009**, 24, 540-8	39
942	Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. **2009**, 1, 371-80	278
941	Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. **2009**, 11, 236-40	77
940	Evaluation of tracer kinetic models for analysis of [18F]FDDNP studies. **2009**, 11, 322-33	19
939	Amyloid imaging in Alzheimer's disease and other dementias. **2009**, 3, 246-61	23

938	Imagerie des r□cepteurs opio□des chez l□homme. **2009**, 22, 248-260		
937	Measurement of central mu-opioid receptor binding in vivo with PET and [11C]carfentanil: a test-retest study in healthy subjects. **2009**, 36, 275-86		55
936	Kinetic modelling of [11C]flumazenil using data-driven methods. **2009**, 36, 659-70		12
935	Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease. **2009**, 36, 1629-38		51
934	Comparative evaluations of norepinephrine transporter radioligands with reference tissue models in rhesus monkeys: (S,S)-[18F]FMeNER-D2 and (S,S)-[11C]MeNER. **2009**, 36, 1885-91		13
933	Selective serotonin reuptake inhibitor (SSRI) modulation of striatal dopamine measured with [11C]-raclopride and positron emission tomography. **2009**, 63, 1-6		17
932	Evaluation of the novel 5-HT4 receptor PET ligand [11C]SB207145 in the G□ttingen minipig. *Journal of Cerebral Blood Flow and Metabolism*, **2009**, 29, 186-96	7.3	49
931	BrainPET Poster Session: Kinetic Modeling. *Journal of Cerebral Blood Flow and Metabolism*, **2009**, 29, S312-S328	7.3	
930	BrainPET Poster Session: in vivo Pharmacology and Clinical Applications. *Journal of Cerebral Blood Flow and Metabolism*, **2009**, 29, S346-S359	7.3	1
929	Modeling considerations for in vivo quantification of the dopamine transporter using [(11)C]PE2I and positron emission tomography. *Journal of Cerebral Blood Flow and Metabolism*, **2009**, 29, 1332-45	7.3	33
928	When what you see isn't what you get: alcohol cues, alcohol administration, prediction error, and human striatal dopamine. **2009**, 33, 139-49		58
927	The dopaminergic basis of human behaviors: A review of molecular imaging studies. **2009**, 33, 1109-32		126
926	Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. **2009**, 29, 14734-40		294
925	Behavioral and neurobiological characteristics influencing social hierarchy formation in female cynomolgus monkeys. **2009**, 158, 1257-65		36
924	Increased brain histamine H1 receptor binding in patients with anorexia nervosa. **2009**, 65, 329-35		39
923	Pharmacokinetics and Modeling. **2009**, 205-214		2
922	Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults. **2009**, 17, 493-502		70
921	Differential FDDNP PET patterns in nondemented middle-aged and older adults. **2009**, 17, 397-406		14

920	Automation of the Logan plot based PiB-PET quantification over multiple subjects and multiple reference regions. **2009**,	
919	A consistent and efficient graphical analysis method to improve the quantification of reversible tracer binding in radioligand receptor dynamic PET studies. **2009**, 44, 661-70	43
918	The distribution of D2/D3 receptor binding in the adolescent rhesus monkey using small animal PET imaging. **2009**, 44, 1334-44	27
917	[18F]flumazenil binding to central benzodiazepine receptor studies by PET--quantitative analysis and comparisons with [11C]flumazenil. **2009**, 45, 891-902	61
916	Hyperstimulation of striatal D2 receptors with sleep deprivation: Implications for cognitive impairment. **2009**, 45, 1232-40	57
915	Traditional Chinese acupuncture and placebo (sham) acupuncture are differentiated by their effects on mu-opioid receptors (MORs). **2009**, 47, 1077-85	203
914	Strategies for the generation of parametric images of [11C]PIB with plasma input functions considering discriminations and reproducibility. **2009**, 48, 329-38	21
913	Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine. **2009**, 4, 101-28	16
912	Positron emission tomography measures of endogenous opioid neurotransmission and impulsiveness traits in humans. **2009**, 66, 1124-34	78
911	A study of non-invasive Patlak quantification for experimental whole-body dynamic FDG-PET studies of mice. **2009**, 42, 216-221	
910	Quantitative analyses of [□□C]Ro15-4513 binding to subunits of GABAA/benzodiazepine receptor in the living human brain. **2009**, 30, 872-80	5
909	Impact of early life stress on the reinforcing and behavioral-stimulant effects of psychostimulants in rhesus monkeys. **2010**, 21, 69-76	10
908	Paired stereoisomer model for quantifying receptor concentration in vivo. **2010**, 37, 1796-806	
907	Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. **2010**, 20, 843-54	187
906	Quantitative analysis of [18F]FDDNP PET using subcortical white matter as reference region. **2010**, 37, 575-88	27
905	Visual assessment of [(11)C]PIB PET in patients with cognitive impairment. **2010**, 37, 1141-7	26
904	Differences in D2 dopamine receptor availability and reaction to novelty in socially housed male monkeys during abstinence from cocaine. **2010**, 208, 585-92	34
903	Characterization of the dopamine receptor system in adult rhesus monkeys exposed to cocaine throughout gestation. **2010**, 210, 481-8	24

902	Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. **2010**, 40, 216-21		179
901	[Neuroimaging: technical aspects and practice]. **2010**, 29, 189-210		10
900	Contact with the bone marrow microenvironment readdresses the fate of transplanted hematopoietic stem cells. **2010**, 38, 968-77		14
899	APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. **2010**, 67, 122-31		618
898	Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. **2010**, 25, 2717-23		82
897	Amyloid imaging of Lewy body-associated disorders. **2010**, 25, 2516-23		118
896	Exercise elevates dopamine D2 receptor in a mouse model of Parkinson's disease: in vivo imaging with [□H]fallypride. **2010**, 25, 2777-84		110
895	Dopamine transporter PET in normal aging: dopamine transporter decline and its possible role in preservation of motor function. **2010**, 64, 146-51		36
894	Positron emission tomography kinetic modeling algorithms for small animal dopaminergic system imaging. **2010**, 64, 200-8		20
893	Endogenous competition against binding of [(18)F]DMFP and [(18)F]fallypride to dopamine D(2/3) receptors in brain of living mouse. **2010**, 64, 313-22		44
892	PET studies of D2-receptor binding in striatal and extrastriatal brain regions: Biochemical support in vivo for separate dopaminergic systems in humans. **2010**, 64, 478-85		15
891	□2-adrenergic drugs modulate the binding of [18F]fallypride to dopamine D2/3 receptors in striatum of living mouse. **2010**, 64, 654-7		7
890	Spinal long-term potentiation is associated with reduced opioid neurotransmission in the rat brain. **2010**, 30, 285-93		12
889	Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. *Journal of Cerebral Blood Flow and Metabolism*, **2010**, 30, 46-50	7.3	197
888	Kinetic modeling of the serotonin 5-HT(1B) receptor radioligand [(11)C]P943 in humans. *Journal of Cerebral Blood Flow and Metabolism*, **2010**, 30, 196-210	7.3	61
887	Measurement of density and affinity for dopamine D(2) receptors by a single positron emission tomography scan with multiple injections of [(11)C]raclopride. *Journal of Cerebral Blood Flow and Metabolism*, **2010**, 30, 663-73	7.3	7
886	In vivo and in vitro validation of reference tissue models for the mGluR(5) ligand [(11)C]ABP688. *Journal of Cerebral Blood Flow and Metabolism*, **2010**, 30, 1538-49	7.3	51
885	Fetal dopamine receptor characteristics assessed in utero. *Journal of Cerebral Blood Flow and Metabolism*, **2010**, 30, 1437-40	7.3	2

884	PET of brain prion protein amyloid in Gerstmann-Str□ssler-Scheinker disease. **2010**, 20, 419-30	42
883	Serotonin-transporter-linked promoter region polymorphism and serotonin transporter binding in drug-na□e patients with major depression. **2010**, 64, 387-93	14
882	Positron emission tomography in schizophrenia: a new perspective. **2010**, 51, 511-20	41
881	Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. **2010**, 23, 185-98	77
880	Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. **2010**, 2, 38ra46	231
879	In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. **2010**, 51, 223-8	103
878	Scanning rodents on the High Resolution Research Tomograph (HRRT) with point spread function reconstruction: A feasibility study. **2010**,	1
877	. **2010**,	
876	Central opioidergic neurotransmission in complex regional pain syndrome. **2010**, 75, 129-36	54
875	Relationship of dementia screening tests with biomarkers of Alzheimer's disease. **2010**, 133, 3290-300	77
874	Validation of the octamouse for simultaneous 18F-fallypride small-animal PET recordings from 8 mice. **2010**, 51, 1576-83	23
873	Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. **2010**, 75, 1920-7	155
872	11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. **2010**, 74, 487-93	118
871	Brain serotonin transporter occupancy by oral sibutramine dosed to steady state: a PET study using (11)C-DASB in healthy humans. **2010**, 35, 741-51	21
870	Dysregulation of regional endogenous opioid function in borderline personality disorder. **2010**, 167, 925-33	111
869	In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. **2010**, 74, 77-84	148
868	Brain mu-opioid receptor binding predicts treatment outcome in cocaine-abusing outpatients. **2010** , 68, 697-703	52
867	18F-fallypride binding potential in patients with schizophrenia compared to healthy controls. **2010**, 122, 43-52	25

866	Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. **2010**, 133, 1111-27	381
865	Dynamic PET denoising with HYPR processing. **2010**, 51, 1147-54	88
864	Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease. **2010**, 31, 1669-78	83
863	Basal opioid receptor binding is associated with differences in sensory perception in healthy human subjects: a [18F]diprenorphine PET study. **2010**, 49, 731-7	32
862	FDDNP binding using MR derived cortical surface maps. **2010**, 49, 240-8	18
861	Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: effects of the novel P-glycoprotein inhibitor tariquidar. **2010**, 49, 1406-15	41
860	Simplified quantification of 5-HT2A receptors in the human brain with [11C]MDL 100,907 PET and non-invasive kinetic analyses. **2010**, 50, 984-93	19
859	Simplified parametric methods for [18F]FDDNP studies. **2010**, 49, 433-41	5
858	Movement correction method for human brain PET images: application to quantitative analysis of dynamic 18F-FDDNP scans. **2010**, 51, 210-8	31
857	Elevated plasma prolactin in abstinent methamphetamine-dependent subjects. **2011**, 37, 62-7	7
856	Molecular Imaging. **2011**,	2
855	Age and disease related changes in the translocator protein (TSPO) system in the human brain: positron emission tomography measurements with [11C]vinpocetine. **2011**, 56, 1111-21	72
854	Effect of oxybutynin and imidafenacin on central muscarinic receptor occupancy and cognitive function: a monkey PET study with [(11)C](+)3-MPB. **2011**, 58, 1-9	20
853	Amyloid affects frontal and posterior brain networks in normal aging. **2011**, 54, 1887-95	90
852	Synthesis, characterization, and monkey positron emission tomography (PET) studies of [18F]Y1-973, a PET tracer for the neuropeptide Y Y1 receptor. **2011**, 54, 2635-42	29
851	Where in-vivo imaging meets cytoarchitectonics: the relationship between cortical thickness and neuronal density measured with high-resolution [18F]flumazenil-PET. **2011**, 56, 951-60	96
850	In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders. **2011**, 31, 4720-30	111
849	Basic Sciences of Nuclear Medicine. **2011**,	15

848	Association of harm avoidance with dopamine D2/3 receptor availability in striatal subdivisions: a high resolution PET study. **2011**, 87, 164-7		30
847	Insulin resistance influences central opioid activity in polycystic ovary syndrome. **2011**, 95, 2494-8		13
846	Differential effects of cocaine and MDMA self-administration on cortical serotonin transporter availability in monkeys. **2011**, 61, 245-51		21
845	An in vivo comparison of cis- and trans-[18F]mefway in the nonhuman primate. **2011**, 38, 925-32		15
844	[18F]Fluoroazabenzoxazoles as potential amyloid plaque PET tracers: synthesis and in vivo evaluation in rhesus monkey. **2011**, 38, 1193-203		19
843	Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements. **2011**, 38, 1149-55		21
842	Effects of age on dopamine D2 receptor availability in striatal subdivisions: a high-resolution positron emission tomography study. **2011**, 21, 885-91		19
841	Increase in hypothalamic aromatase in macaque monkeys treated with anabolic-androgenic steroids: PET study with [11C]vorozole. **2011**, 22, 326-30		7
840	Antipsychotic-associated mental side effects and their relationship to dopamine D2 receptor occupancy in striatal subdivisions: a high-resolution PET study with [11C]raclopride. **2011**, 31, 507-11		19
839	Role of family history for Alzheimer biomarker abnormalities in the adult children study. **2011**, 68, 1313-9		46
838	Amyloid-and glucose metabolism in Alzheimer's disease. **2011**, 26 Suppl 3, 105-16		19
837	Midbrain serotonin transporters in de novo and L-DOPA-treated patients with early Parkinson's disease--a [123 I]-ADAM SPECT study. **2011**, 18, 750-5		9
836	Positron emission tomography imaging of mu- and delta-opioid receptor binding in alcohol-dependent and healthy control subjects. **2011**, 35, 2162-73		75
835	The use of alternative forms of graphical analysis to balance bias and precision in PET images. *Journal of Cerebral Blood Flow and Metabolism*, **2011**, 31, 535-46	7.3	15
834	Silent cortical neuronal damage in atherosclerotic disease of the major cerebral arteries. *Journal of Cerebral Blood Flow and Metabolism*, **2011**, 31, 953-61	7.3	25
833	Quantitative analysis of [11C]AZ10419369 binding to 5-HT1B receptors in human brain. *Journal of Cerebral Blood Flow and Metabolism*, **2011**, 31, 113-23	7.3	68
832	Serotonergic mediated body mass index changes in Parkinson's disease. **2011**, 43, 609-15		36
831	Face-name associative memory performance is related to amyloid burden in normal elderly. **2011**, 49, 2776-83		145

830	Naloxone-induced cortisol predicts mu opioid receptor binding potential in specific brain regions of healthy subjects. **2011**, 36, 1453-9	27
829	PET kinetics of radiolabeled antidepressant, [N-methyl-11C]mirtazapine, in the human brain. **2011**, 1, 36	2
828	In vivo positron emission tomography imaging with [□□C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons. **2011**, 38, 1083-94	47
827	Active cyamemazine metabolites in patients treated with cyamemazine (Tercian□): influence on cerebral dopamine D2 and serotonin 5-HT (2A) receptor occupancy as measured by positron emission tomography (PET). **2011**, 217, 315-21	3
826	Validation of reference tissue modelling for [11C]flumazenil positron emission tomography following head injury. **2011**, 25, 396-405	16
825	Test-retest variability of [□□C]raclopride-binding potential in nontreatment-seeking alcoholics. **2011**, 65, 553-61	22
824	In vivo kinetics of [F-18]MEFWAY: a comparison with [C-11]WAY100635 and [F-18]MPPF in the nonhuman primate. **2011**, 65, 592-600	35
823	Validation of reference tissue model of PET ligand [□□C]+3-MPB for the muscarinic cholinergic receptor in the living brain of conscious monkey. **2011**, 65, 548-51	5
822	Striatal and extrastriatal microPET imaging of D2/D3 dopamine receptors in rat brain with [□□]fallypride and [□□]desmethoxyfallypride. **2011**, 65, 778-87	30
821	Imaging of alcohol-induced dopamine release in rats:preliminary findings with [(11) C]raclopride PET. **2011**, 65, 929-37	5
820	Specific □□ nicotinic acetylcholine receptor binding of [F-18]nifene in the rhesus monkey. **2011**, 65, 1309-18	27
819	Decreased striatal dopamine receptor binding in primary focal dystonia: a D2 or D3 defect?. **2011**, 26, 100-6	36
818	Practical synthesis of precursor of [N-methyl-11C]vorozole, an efficient PET tracer targeting aromatase in the brain. **2011**, 19, 1464-70	22
817	Assessment of i.p. injection of [18F]fallypride for behavioral neuroimaging in rats. **2011**, 196, 70-5	8
816	Selective neuronal damage and Wisconsin Card Sorting Test performance in atherosclerotic occlusive disease of the major cerebral artery. **2011**, 82, 150-6	14
815	Using positron emission tomography and Carbon 11-labeled Pittsburgh Compound B to image Brain Fibrillar □amyloid in adults with down syndrome: safety, acceptability, and feasibility. **2011**, 68, 890-6	57
814	Reference tissue modeling with parameter coupling: application to a study of SERT binding in HIV. **2011**, 56, 2499-513	4
813	Relationships between □amyloid and functional connectivity in different components of the default mode network in aging. **2011**, 21, 2399-407	229

812	PET of (R)-11C-rolipram binding to phosphodiesterase-4 is reproducible and sensitive to increased norepinephrine in the rat heart. **2011**, 52, 263-9		16
811	Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. **2011**, 68, 1137-44		138
810	Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. **2011**, 52, 173-9		60
809	Molecular Brain Imaging of Personality Traits in Nonhuman Primates: A Study of the Common Marmoset. **2011**, 389-406		2
808	From Genes to Animal Behavior. **2011**,		3
807	Protein binding in patients with late-life depression. **2011**, 68, 1143-50		60
806	Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. **2011**, 134, 3290-8		102
805	Human dosimetry and preliminary tumor distribution of 18F-fluoropaclitaxel in healthy volunteers and newly diagnosed breast cancer patients using PET/CT. **2011**, 52, 1339-45		25
804	In vivo variation in metabotropic glutamate receptor subtype 5 binding using positron emission tomography and [11C]ABP688. *Journal of Cerebral Blood Flow and Metabolism*, **2011**, 31, 2169-80	7.3	59
803	Validation and quantification of [18F]altanserin binding in the rat brain using blood input and reference tissue modeling. *Journal of Cerebral Blood Flow and Metabolism*, **2011**, 31, 2334-42	7.3	19
802	Quantitative, preclinical PET of translocator protein expression in glioma using 18F-N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline. **2011**, 52, 107-14		54
801	Noninvasive nuclear imaging enables the in vivo quantification of striatal dopamine receptor expression and raclopride affinity in mice. **2011**, 52, 1133-41		26
800	11C-(R)-PK11195 PET imaging of microglial activation and response to minocycline in zymosan-treated rats. **2011**, 52, 257-62		21
799	Muscarinic receptor occupancy and cognitive impairment: a PET study with [11C](+)3-MPB and scopolamine in conscious monkeys. **2011**, 36, 1455-65		21
798	11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. **2012**, 53, 538-45		111
797	Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone. **2012**, 341, 81-9		19
796	Methodology Poster Abstracts. *Journal of Cerebral Blood Flow and Metabolism*, **2012**, 32, S128-S191	7.3	2
795	Quantification of ligand PET studies using a reference region with a displaceable fraction: application to occupancy studies with [(11)C]-DASB as an example. *Journal of Cerebral Blood Flow and Metabolism*, **2012**, 32, 70-80	7.3	28

794	Chronic Δ-tetrahydrocannabinol exposure induces a sensitization of dopamine D2 receptors in the mesoaccumbens and nigrostriatal systems. **2012**, 37, 2355-67		41
793	Measurement of 5-HT(1A) receptor density and in-vivo binding parameters of [(18)F]mefway in the nonhuman primate. *Journal of Cerebral Blood Flow and Metabolism*, **2012**, 32, 1546-58	7.3	12
792	Chronic treatment with extended release methylphenidate does not alter dopamine systems or increase vulnerability for cocaine self-administration: a study in nonhuman primates. **2012**, 37, 2555-65		42
791	Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. **2012**, 4, 128ra41		92
790	PET imaging of α4β2* nicotinic acetylcholine receptors: quantitative analysis of 18F-nifene kinetics in the nonhuman primate. **2012**, 53, 1471-80		22
789	In vivo dopamine transporter imaging in a unilateral 6-hydroxydopamine rat model of Parkinson disease using 11C-methylphenidate PET. **2012**, 53, 813-22		14
788	Feasibility and dosimetry studies for 18F-NOS as a potential PET radiopharmaceutical for inducible nitric oxide synthase in humans. **2012**, 53, 994-1001		22
787	Assessment of striatal dopamine D2/D3 receptor availability with PET and 18F-desmethoxyfallypride: comparison of imaging protocols suited for clinical routine. **2012**, 53, 1558-64		2
786	Association of lifetime cognitive engagement and low β-amyloid deposition. **2012**, 69, 623-29		225
785	Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. **2012**, 64, 27-81		66
784	Pattern of cardiac sympathetic denervation in idiopathic Parkinson disease studied with 11C hydroxyephedrine PET. **2012**, 265, 240-7		27
783	Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens. **2012**, 4, 116ra6		148
782	Antiparkinsonian mechanism of electroconvulsive therapy in MPTP-lesioned non-human primates. **2012**, 9, 128-38		6
781	Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. **2012**, 69, 215-22		59
780	Improved tumor contrast achieved by single time point dual-reporter fluorescence imaging. **2012**, 17, 066001		45
779	Subacute ischemic stroke is associated with focal 11C PiB positron emission tomography retention but not with global neocortical Aβ deposition. **2012**, 43, 1341-6		29
778	PET evidence for a role for striatal dopamine in the attentional blink: functional implications. **2012**, 24, 1932-40		36
777	Irrational choice under uncertainty correlates with lower striatal D(2/3) receptor binding in rats. **2012**, 32, 15450-7		67

776	Differential modulation of the default mode network via serotonin-1A receptors. **2012**, 109, 2619-24	92
775	Evidence that sleep deprivation downregulates dopamine D2R in ventral striatum in the human brain. **2012**, 32, 6711-7	151
774	Quantitative preclinical imaging of TSPO expression in glioma using N,N-diethyl-2-(2-(4-(2-18F-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide. **2012**, 53, 287-94	54
773	PET and MRI reveal early evidence of neurodegeneration in spinocerebellar ataxia type 17. **2012**, 53, 1074-80	37
772	Clinical validation of 18F-AZD4694, an amyloid-β specific PET radioligand. **2012**, 53, 415-24	172
771	Dissociative changes in the Bmax and KD of dopamine D2/D3 receptors with aging observed in functional subdivisions of the striatum: a revisit with an improved data analysis method. **2012**, 53, 805-12	10
770	Relative equilibrium plot improves graphical analysis and allows bias correction of standardized uptake value ratio in quantitative 11C-PiB PET studies. **2012**, 53, 622-8	14
769	Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. **2012**, 69, 223-9	220
768	Aβ Deposition in aging is associated with increases in brain activation during successful memory encoding. **2012**, 22, 1813-23	105
767	Advantages of a dual-tracer model over reference tissue models for binding potential measurement in tumors. **2012**, 57, 6647-59	24
766	Recent software developments and applications in functional imaging. **2012**, 13, 2166-81	1
765	Parametric [11C]flumazenil images. **2012**, 33, 422-30	9
764	Immediate effects of tDCS on the μ opioid system of a chronic pain patient. **2012**, 3, 93	67
763	Positron emission tomography study of the effects of tryptophan depletion on brain serotonin(2) receptors in subjects recently remitted from major depression. **2012**, 69, 601-9	14
762	Self-reported memory impairment and brain PET of amyloid and tau in middle-aged and older adults without dementia. **2012**, 24, 1076-84	22
761	Prediction of cognitive decline based on hemispheric cortical surface maps of FDDNP PET. **2012**, 61, 749-60	10
760	In vivo quantification of tumor receptor binding potential with dual-reporter molecular imaging. **2012**, 14, 584-92	82
759	Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. **2012**, 50, 2880-2886	318

758	Development of N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methyl-4-[11C]methylbenzamide for positron emission tomography imaging of metabotropic glutamate 1 receptor in monkey brain. **2012**, 55, 11042-51	28
757	Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. **2012**, 33, 215-25	108
756	Cerebrovascular disease, amyloid, and cognition in aging. **2012**, 33, 1006.e25-36	88
755	Coronary risk correlates with cerebral amyloid deposition. **2012**, 33, 1979-87	55
754	Toward a multifactorial model of Alzheimer disease. **2012**, 33, 2262-71	42
753	Effects of age and amyloid on cognitive changes in normal elderly people. **2012**, 33, 2746-55	34
752	Simplified quantification and whole-body distribution of [18F]FE-PE2I in nonhuman primates: prediction for human studies. **2012**, 39, 295-303	13
751	Tobacco smoking produces greater striatal dopamine release in G-allele carriers with mu opioid receptor A118G polymorphism. **2012**, 38, 236-40	35
750	A amyloid deposition in patients with Parkinson disease at risk for development of dementia. **2012**, 79, 1161-7	84
749	PET amyloid-beta imaging in preclinical Alzheimer's disease. **2012**, 1822, 370-9	102
748	A study of non-invasive Patlak quantification for whole-body dynamic FDG-PET studies of mice. **2012**, 7, 438-446	6
747	Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. **2012**, 59, 1152-60	116
746	In vivo quantification of dopamine transporters in mice with unilateral 6-OHDA lesions using [11C]methylphenidate and PET. **2012**, 59, 2413-22	16
745	Quantitative PET analyses of regional [11C]PE2I binding to the dopamine transporter--application to juvenile myoclonic epilepsy. **2012**, 59, 3582-93	27
744	Comparative evaluation of Logan and relative-equilibrium graphical methods for parametric imaging of dynamic [18F]FDDNP PET determinations. **2012**, 60, 241-51	4
743	Combining image-derived and venous input functions enables quantification of serotonin-1A receptors with [carbonyl-11C]WAY-100635 independent of arterial sampling. **2012**, 62, 199-206	14
742	Quantification of dopamine D(2/3) receptors in rat brain using factor analysis corrected [18F]Fallypride images. **2012**, 62, 1455-68	21
741	Imaging DA release in a rat model of L-DOPA-induced dyskinesias: a longitudinal in vivo PET investigation of the antidyskinetic effect of MDMA. **2012**, 63, 423-33	9

740	[18F]desmethoxyfallypride as a novel PET radiotracer for quantitative in vivo dopamine D2/D3 receptor imaging in rat models of neurodegenerative diseases. **2012**, 39, 1077-80	9
739	Evolution of microglial activation in ischaemic core and peri-infarct regions after stroke: a PET study with the TSPO molecular imaging biomarker [((11))C]vinpocetine. **2012**, 320, 110-7	59
738	Quantitative assessment of dynamic PET imaging data in cancer imaging. **2012**, 30, 1203-15	58
737	Quantification of Neuroreceptors and Neurotransporters. **2012**, 149-161	1
736	Scanning rats on the high resolution research tomograph (HRRT): a comparison study with a dedicated micro-PET. **2012**, 39, 5073-83	16
735	Reduced basal ganglia □opioid receptor availability in trigeminal neuropathic pain: a pilot study. **2012**, 8, 74	41
734	Quantitative analysis and comparison study of [18F]AlF-NOTA-PRGD2, [18F]FPPRGD2 and [68Ga]Ga-NOTA-PRGD2 using a reference tissue model. **2012**, 7, e37506	41
733	Reduction of [11C](+)3-MPB binding in brain of chronic fatigue syndrome with serum autoantibody against muscarinic cholinergic receptor. **2012**, 7, e51515	30
732	Visualising neuroinflammation in post-stroke patients: a comparative PET study with the TSPO molecular imaging biomarkers [11C]PK11195 and [11C]vinpocetine. **2012**, 5, 19-28	37
731	Automated VOI Analysis in FDDNP PET Using Structural Warping: Validation through Classification of Alzheimer's Disease Patients. **2012**, 2012, 512069	3
730	Dynamic PET and Optical Imaging and Compartment Modeling using a Dual-labeled Cyclic RGD Peptide Probe. **2012**, 2, 746-56	28
729	GABA(A) receptors in visual and auditory cortex and neural activity changes during basic visual stimulation. **2012**, 6, 337	15
728	Cerebral amyloid deposition and serotoninergic innervation in Parkinson disease. **2012**, 69, 1628-31	12
727	Improved kinetic analysis of dynamic PET data with optimized HYPR-LR. **2012**, 39, 3319-31	29
726	Nicotinic acetylcholine receptors in rat forebrain that bind □H-nifene: relating PET imaging, autoradiography, and behavior. **2012**, 66, 418-34	22
725	Test-retest stability of cerebral mGluR□quantification using [□□C]ABP688 and positron emission tomography in rats. **2012**, 66, 552-60	30
724	Characterization of extrastriatal D2 in vivo specific binding of [□H](N-methyl)benperidol using PET. **2012**, 66, 770-80	34
723	Brain amyloid and cognition in Lewy body diseases. **2012**, 27, 965-73	128

722	Assessment of dementia risk in aging adults using both FDG-PET and FDDNP-PET imaging. **2012**, 27, 1017-27	6
721	Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. **2012**, 71, 560-8	170
720	Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future. **2012**, 14, 131-46	73
719	Decreased microglial activation in MS patients treated with glatiramer acetate. **2012**, 259, 1199-205	68
718	Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning. **2012**, 120, 806-17	35
717	[18F]Fallypride PET measurement of striatal and extrastriatal dopamine D 2/3 receptor availability in recently abstinent alcoholics. **2012**, 17, 490-503	44
716	Dopamine pathway loss in nucleus accumbens and ventral tegmental area predicts apathetic behavior in MPTP-lesioned monkeys. **2012**, 236, 190-7	50
715	Characterisation of [□□C]PR04.MZ in Papio anubis baboon: a selective high-affinity radioligand for quantitative imaging of the dopamine transporter. **2012**, 22, 679-82	6
714	Model-independent plot of dynamic PET data facilitates data interpretation and model selection. **2012**, 295, 1-8	1
713	Serotonin transporter binding after recovery from bulimia nervosa. **2012**, 45, 345-52	17
712	Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. **2012**, 123, 433-47	74
711	Introduction to the analysis of PET data in oncology. **2013**, 40, 419-36	4
710	Modeling of PET data in CNS drug discovery and development. **2013**, 40, 267-79	28
709	Evaluation of serotonin 5-HT(1A) receptors in rodent models using [□□]mefway PET. **2013**, 67, 596-608	18
708	Quantitative positron emission tomography imaging of angiogenesis in rats with forelimb ischemia using (68)Ga-NOTA-c(RGDyK). **2013**, 16, 837-46	12
707	PET imaging of the brain serotonin transporters (SERT) with N,N-dimethyl-2-(2-amino-4-[18F]fluorophenylthio)benzylamine (4-[18F]-ADAM) in humans: a preliminary study. **2013**, 40, 115-24	23
706	Analysis of 5-HT(2A) receptor binding with [(11)C]MDL 100907 in rats: optimization of kinetic modeling. **2013**, 15, 730-8	6
705	Suitability of [18F]altanserin and PET to determine 5-HT2A receptor availability in the rat brain: in vivo and in vitro validation of invasive and non-invasive kinetic models. **2013**, 15, 456-67	9

704	GABA(A) receptor imaging with positron emission tomography in the human newborn: a unique binding pattern. **2013**, 48, 459-62	12
703	Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing Swedish mutant β-amyloid precursor protein using 18F-florbetaben PET. **2013**, 54, 1127-34	65
702	Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease. **2013**, 136, 3282-9	105
701	Frontotemporal network connectivity during memory encoding is increased with aging and disrupted by beta-amyloid. **2013**, 33, 18425-37	47
700	Dopamine asymmetries predict orienting bias in healthy individuals. **2013**, 23, 2899-904	39
699	Prenatal stress induces increased striatal dopamine transporter binding in adult nonhuman primates. **2013**, 74, 502-10	19
698	Concordance between in vivo and postmortem measurements of cholinergic denervation in rats using PET with [18F]FEOBV and choline acetyltransferase immunochemistry. **2013**, 3, 70	12
697	Imaging the role of GABA in movement disorders. **2013**, 13, 385	16
696	Noninvasive k3 estimation method for slow dissociation PET ligands: application to [11C]Pittsburgh compound B. **2013**, 3, 76	
695	Amyloid imaging in clinical trials. **2013**, 5, 36	14
694	Microglial activation in Alzheimer's disease: an (R)-[□□C]PK11195 positron emission tomography study. **2013**, 34, 128-36	126
693	Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. **2013**, 80, 85-91	124
692	□valuation quantitative pr□liminaire du 18F-FDDNP en TEP/TDM dans la maladie d□Alzheimer, en utilisant diff□entes r□gions de r□□ence. **2013**, 37, 578-585	
691	Lack of endogenous opioid release during sustained visceral pain: a [11C]carfentanil PET study. **2013**, 154, 2072-2077	9
690	Grey matter density and GABAA binding potential show a positive linear relationship across cortical regions. **2013**, 235, 226-31	9
689	Graphic plot analysis for estimating binding potential of translocator protein (TSPO) in positron emission tomography studies with [□]FEDAA1106. **2013**, 69, 78-86	5
688	The pattern of striatal dopaminergic denervation explains sensorimotor synchronization accuracy in Parkinson's disease. **2013**, 257, 100-10	16
687	Validation of parametric methods for [□□C]PE2I positron emission tomography. **2013**, 74, 172-8	8

686	Effects of acute detoxification of the herbal blend 'Spice Gold' on dopamine D2/3 receptor availability: a [18F]fallypride PET study. **2013**, 23, 1606-10		30
685	In vivo evaluation of [(123)I]MNI-420: a novel single photon emission computed tomography radiotracer for imaging of adenosine 2A receptors in brain. **2013**, 40, 403-9		14
684	The effect of amyloid on cognitive decline is modulated by neural integrity in cognitively normal elderly. **2013**, 9, 687-698.e1		55
683	Diabetes is associated with postural instability and gait difficulty in Parkinson disease. **2013**, 19, 522-6		65
682	Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. **2013**, 28, 296-301		66
681	Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not amyloid in cognitively normal older individuals. **2013**, 33, 5553-63		113
680	Gender differences in cholinergic and dopaminergic deficits in Parkinson disease. **2013**, 120, 1421-4		13
679	Early deficits in declarative and procedural memory dependent behavioral function in a transgenic rat model of Huntington's disease. **2013**, 239, 15-26		19
678	Measuring dopaminergic function in the 6-OHDA-lesioned rat: a comparison of PET and microdialysis. **2013**, 3, 69		14
677	Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. **2013**, 136, 844-58		235
676	Amyloid-positron emission tomography imaging probes: a critical review. **2013**, 36, 613-31		56
675	Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. **2013**, 80, 1850-5		76
674	Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases. **2013**, 81, 520-7		32
673	The aging brain and cognition: contribution of vascular injury and ato mild cognitive dysfunction. **2013**, 70, 488-95		98
672	Reference region approaches in PET: a comparative study on multiple radioligands. *Journal of Cerebral Blood Flow and Metabolism*, **2013**, 33, 888-97	7.3	48
671	First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. **2013**, 54, 691-8		134
670	Preclinical Alzheimer disease and risk of falls. **2013**, 81, 437-43		53
669	Effects of anesthesia and species on the uptake or binding of radioligands in vivo in the Gttingen minipig. **2013**, 2013, 808713		16

668	Reference region automatic extraction in dynamic [(11)C]PIB. *Journal of Cerebral Blood Flow and Metabolism*, **2013**, 33, 1725-31	7.3	18
667	Kinetic modeling, test-retest, and dosimetry of 123I-MNI-420 in humans. **2013**, 54, 1760-7		14
666	Synthesis and evaluation of 18F-FE-PEO in rodents: an 18F-labeled full agonist for opioid receptor imaging. **2013**, 54, 299-305		18
665	Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease. **2013**, 54, 1434-41		61
664	Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for □amyloid imaging in aging and dementia. **2013**, 54, 880-6		121
663	Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. **2013**, 70, 1512-9		119
662	Nonlinear spatio-temporal filtering of dynamic PET data using a four-dimensional Gaussian filter and expectation-maximization deconvolution. **2013**, 58, 1151-68		3
661	Assessment of cellular proliferation in tumors by PET using 18F-ISO-1. **2013**, 54, 350-7		64
660	Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. **2013**, 54, 1570-6		115
659	Metabolism of epidermal growth factor receptor targeting probe [11C]PD153035: impact on biodistribution and tumor uptake in rats. **2013**, 54, 1804-11		5
658	Dynamic dual-tracer MRI-guided fluorescence tomography to quantify receptor density in vivo. **2013**, 110, 9025-30		67
657	Denicotinized versus average nicotine tobacco cigarette smoking differentially releases striatal dopamine. **2013**, 15, 11-21		20
656	A comparison of D2 receptor specific binding in obese and normal-weight individuals using PET with (N-[(11)C]methyl)benperidol. **2013**, 67, 748-56		66
655	Validation of nigrostriatal positron emission tomography measures: critical limits. **2013**, 73, 390-6		55
654	The influence of time sampling on parameters in the Logan plot. **2013**,		
653	Catechol-O-methyltransferase genotype modulates opioid release in decision circuitry. **2013**, 6, 400-3		11
652	individual variation in sleep quality and duration is related to cerebral mu opioid receptor binding potential during tonic laboratory pain in healthy subjects. **2013**, 14, 1882-92		21
651	Alterations in endogenous opioid functional measures in chronic back pain. **2013**, 33, 14729-37		42

650	In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET. *Journal of Cerebral Blood Flow and Metabolism*, **2013**, 33, 59-66	7.3	21
649	The simplified reference tissue model with 18F-fallypride positron emission tomography: choice of reference region. **2013**, 12,		14
648	Molecular Imaging PET and SPECT Approaches for Improving Productivity of Antipsychotic Drug Discovery and Development. **2013**, 20, 378-388		6
647	Treadmill exercise elevates striatal dopamine D2 receptor binding potential in patients with early Parkinson's disease. **2013**, 24, 509-14		139
646	Postmortem 3-D brain hemisphere cortical tau and amyloid-β pathology mapping and quantification as a validation method of neuropathology imaging. **2013**, 36, 261-74		26
645	Vascular risk and FDDNP-PET influence cognitive performance. **2013**, 35, 147-57		3
644	Associations between white matter hyperintensities and β amyloid on integrity of projection, association, and limbic fiber tracts measured with diffusion tensor MRI. **2013**, 8, e65175		63
643	Quantitative analysis of PiB-PET with FreeSurfer ROIs. **2013**, 8, e73377		126
642	PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. **2013**, 36, 145-53		82
641	How to Study Smoking and Drinking with PET. **2013**,		2
640	Human Brain Imaging of Adenosine Receptors. **2014**, 161-186		
639	Differential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. **2014**, 9, e90759		14
638	Mu Opioid Receptor Binding Correlates with Nicotine Dependence and Reward in Smokers. **2014**, 9, e113694		32
637	Quantitative preclinical PET imaging: opportunities and challenges. **2014**, 2,		37
636	Imaging Brain Metabolism and Pathology in Alzheimer's Disease with Positron Emission Tomography. **2014**, 4,		11
635	Functional brain imaging and its application to uncover mechanisms driving food intake in humans. **2014**, 4,		2
634	Physiological Modelling of Positron Emission Tomography Images. **2014**, 417-448		1
633	In vivo quantification of cerebral translocator protein binding in humans using 6-chloro-2-(4'-123I-iodophenyl)-3-(N,N-diethyl)-imidazo[1,2-a]pyridine-3-acetamide SPECT. **2014**, 55, 1966-72		14

632	Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteers. **2014**, 78, 970-80		42
631	Test-retest variability of adenosine A2A binding in the human brain with (11)C-TMSX and PET. **2014**, 4, 76		13
630	Noninvasive quantification of metabotropic glutamate receptor type 1 with [¹¹C]ITDM: a small-animal PET study. *Journal of Cerebral Blood Flow and Metabolism*, **2014**, 34, 606-12	7.3	17
629	Radiosynthesis and validation of ¹⁸F-FP-CMT, a phenyltropane with superior properties for imaging the dopamine transporter in living brain. *Journal of Cerebral Blood Flow and Metabolism*, **2014**, 34, 1148-56	7.3	13
628	Effects of Beta-Amyloid on Resting State Functional Connectivity Within and Between Networks Reflect Known Patterns of Regional Vulnerability. **2016**, 26, 695-707		63
627	First-in-human evaluation of 18F-mefway, a PET radioligand specific to serotonin-1A receptors. **2014**, 55, 1973-9		13
626	Human Brain Imaging of Dopamine Transporters. **2014**, 203-240		4
625	Comparison of methods for evaluating radiolabelled Annexin A5 uptake in pre-clinical PET oncological studies. **2014**, 41, 793-800		4
624	Is verbal episodic memory in elderly with amyloid deposits preserved through altered neuronal function?. **2014**, 24, 2210-8		30
623	Love to win or hate to Lose? Asymmetry of dopamine D2 receptor binding predicts sensitivity to reward versus punishment. **2014**, 26, 1039-48		47
622	Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients. **2014**, 85, 266-73		40
621	Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. **2014**, 124, 1340-9		172
620	Cortical thickness mediates the effect of β-amyloid on episodic memory. **2014**, 82, 761-7		33
619	Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury. **2014**, 71, 23-31		112
618	Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates. **2014**, 76, 393-402		50
617	Recent advances in parametric neuroreceptor mapping with dynamic PET: basic concepts and graphical analyses. **2014**, 30, 733-54		7
616	Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis. **2014**, 270, 849-56		122
615	Association of adenosine receptor gene polymorphisms and in vivo adenosine A1 receptor binding in the human brain. **2014**, 39, 2989-99		20

614	□Opioid activation in the midbrain during migraine allodynia - brief report II. **2014**, 1, 445-50	17
613	Association of □Opioid Activation in the Prefrontal Cortex with Spontaneous Migraine Attacks - Brief Report I. **2014**, 1, 439-444	24
612	Cortical dopamine release during a behavioral response inhibition task. **2014**, 68, 266-74	30
611	Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging. **2014**, 4, 483-98	27
610	Dopamine Receptors and Dopamine Release. **2014**, 289-339	1
609	Dopamine D(2/3) receptor availability and human cognitive impulsivity: a high-resolution positron emission tomography imaging study with [□□C]raclopride. **2014**, 26, 35-42	18
608	Human brain imaging of □7 nAChR with [(18)F]ASEM: a new PET radiotracer for neuropsychiatry and determination of drug occupancy. **2014**, 16, 730-8	57
607	Assessment of cerebral dopamine D 2/3 formula-receptors in patients with bilateral vestibular failure. **2014**, 24, 403-13	8
606	External awareness and GABA--a multimodal imaging study combining fMRI and [18F]flumazenil-PET. **2014**, 35, 173-84	26
605	Covarying alterations in A□deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. **2014**, 35, 297-308	66
604	FAAH selectively influences placebo effects. **2014**, 19, 385-91	64
603	Risky driving and pedunculopontine nucleus-thalamic cholinergic denervation in Parkinson disease. **2014**, 20, 13-6	7
602	Biodistribution studies of two 18F-labeled pyridinylphenyl amides as subtype selective radioligands for the dopamine D3 receptor. **2014**, 41, 223-8	13
601	PET imaging with [□F]fluoroethoxybenzovesamicol ([□F]FEOBV) following selective lesion of cholinergic pedunculopontine tegmental neurons in rat. **2014**, 41, 96-101	16
600	In vivo PET quantification of the dopamine transporter in rat brain with [□F]LBT-999. **2014**, 41, 106-13	14
599	Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease. **2014**, 66, 19-27	12
598	History of childhood adversity is positively associated with ventral striatal dopamine responses to amphetamine. **2014**, 231, 2417-33	73
597	Direct characterization of arterial input functions by fluorescence imaging of exposed carotid artery to facilitate kinetic analysis. **2014**, 16, 488-94	4

596	Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study. **2014**, 231, 2299-310		11
595	Tumor endothelial marker imaging in melanomas using dual-tracer fluorescence molecular imaging. **2014**, 16, 372-82		15
594	Diagnostic utility of amyloid PET in cerebral amyloid angiopathy-related symptomatic intracerebral hemorrhage. *Journal of Cerebral Blood Flow and Metabolism*, **2014**, 34, 753-8	7.3	42
593	Accounting for pharmacokinetic differences in dual-tracer receptor density imaging. **2014**, 59, 2341-51		19
592	Advanced age, cardiovascular risk burden, and timed up and go test performance in Parkinson disease. **2014**, 69, 1569-75		10
591	Imaging nicotine- and amphetamine-induced dopamine release in rhesus monkeys with [(11)C]PHNO vs [(11)C]raclopride PET. **2014**, 39, 866-74		36
590	Association of gray matter atrophy with age, β-amyloid, and cognition in aging. **2014**, 24, 1609-18		52
589	A possible mechanism of the nucleus accumbens and ventral pallidum 5-HT1B receptors underlying the antidepressant action of ketamine: a PET study with macaques. **2014**, 4, e342		55
588	Longitudinal PET-MRI reveals β-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion. **2014**, 20, 1485-92		87
587	Gene-environment interactions: lifetime cognitive activity, APOE genotype, and β-amyloid burden. **2014**, 34, 8612-7		93
586	In Vivo Brain Imaging in Animal Models: A Focus on PET and MRI. **2014**, 149-166		
585	In vivo evaluation of 18F-MNI698: an 18F-labeled radiotracer for imaging of serotonin 4 receptors in brain. **2014**, 55, 858-64		15
584	Simultaneous fMRI-PET of the opioidergic pain system in human brain. **2014**, 102 Pt 2, 275-82		43
583	Umbilical Cord Blood Banking and Transplantation. **2014**,		1
582	Synthesis and evaluation of (13)N-labelled azo compounds for β-amyloid imaging in mice. **2014**, 16, 538-49		14
581	Deriving physiological information from PET images: from SUV to compartmental modelling. **2014**, 2, 239-251		21
580	In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer's disease with a high specific activity PET imaging agent [(18)F]flutemetamol. **2014**, 4, 37		19
579	Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease. **2014**, 82, 1514-20		58

578	Neural compensation in older people with brain amyloid-β deposition. **2014**, 17, 1316-8		123
577	In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs. **2014**, 57, 7999-8009		61
576	In vivo imaging of human cholinergic nerve terminals with (-)-5-(18)F-fluoroethoxybenzovesamicol: biodistribution, dosimetry, and tracer kinetic analyses. **2014**, 55, 396-404		83
575	Discovery and development of 11C-Lu AE92686 as a radioligand for PET imaging of phosphodiesterase10A in the brain. **2014**, 55, 1513-8		31
574	Reproducibility of non-invasive a1 adenosine receptor quantification in the rat brain using [(18)F]CPFPX and positron emission tomography. **2014**, 16, 699-709		11
573	Neurobiology of placebo effects: expectations or learning?. **2014**, 9, 1013-21		37
572	Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An [11]C-(R)-PK11195 PET Study. **2014**, 55, 945-50		179
571	Spinal cord dopamine D2/D3 receptors: in vivo and ex vivo imaging in the rat using (18)F/(11)C-fallypride. **2014**, 41, 841-7		6
570	11C-cetrozole: an improved C-11C-methylated PET probe for aromatase imaging in the brain. **2014**, 55, 852-7		25
569	Surface-based partial-volume correction for high-resolution PET. **2014**, 102 Pt 2, 674-87		17
568	Neuroprotective pathways: lifestyle activity, brain pathology, and cognition in cognitively normal older adults. **2014**, 35, 1873-82		82
567	Characterization of [(11)C]Cimbi-36 as an agonist PET radioligand for the 5-HT(2A) and 5-HT(2C) receptors in the nonhuman primate brain. **2014**, 84, 342-53		48
566	Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36. *Journal of Cerebral Blood Flow and Metabolism*, **2014**, 34, 1188-96	7.3	68
565	Quantification of dopamine transporter density with [18F]FECNT PET in healthy humans. **2014**, 41, 217-22		10
564	Psychological well-being and regional brain amyloid and tau in mild cognitive impairment. **2014**, 22, 362-9		7
563	Basal μ-opioid receptor availability in the amygdala predicts the inhibition of pain-related brain activity during heterotopic noxious counter-stimulation. **2014**, 81-82, 78-84		14
562	In vivo measures of nigrostriatal neuronal response to unilateral MPTP treatment. **2014**, 1571, 49-60		8
561	Kinetic modeling in pre-clinical positron emission tomography. **2014**, 24, 274-85		13

560	Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology. **2014**, 4, 508-16	41
559	Quantification of GABAA receptors in the rat brain with [(123)I]Iomazenil SPECT from factor analysis-denoised images. **2014**, 41, 186-95	13
558	Amyloid burden and neural function in people at risk for Alzheimer's Disease. **2014**, 35, 576-84	117
557	[□E]Altanserin and small animal PET: impact of multidrug efflux transporters on ligand brain uptake and subsequent quantification of 5-HT□A receptor densities in the rat brain. **2014**, 41, 1-9	11
556	Evaluation of P-glycoprotein (abcb1a/b) modulation of [(18)F]fallypride in MicroPET imaging studies. **2014**, 84, 152-8	9
555	Extrastriatal dopaminergic changes in Parkinson's disease patients with impulse control disorders. **2014**, 85, 23-30	35
554	D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. **2014**, 19, 176-81	16
553	3D-neuronavigation in vivo through a patient's brain during a spontaneous migraine headache. **2014**,	9
552	Dual-tracer receptor concentration imaging using tracers with different tissue delivery kinetics. **2014**,	
551	A modified simplified reference tissue model for the quantification of dopamine D2/3 receptors with [18F]fallypride images. **2014**, 13,	2
550	Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults. **2015**, 29, 368-81	23
549	Characterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [□C]ABP688. **2015**, 5, e693	27
548	Exploring the effects of coexisting amyloid in subcortical vascular cognitive impairment. **2015**, 15, 197	7
547	Challenges of quantification of TSPO in the human brain. **2015**, 3, 403-416	15
546	In vivo quantification of the [(11)C]DASB binding in the normal canine brain using positron emission tomography. **2015**, 11, 308	3
545	Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging. **2015**, 12, 108	40
544	Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. **2015**, 77, 338-42	106
543	Light therapy and serotonin transporter binding in the anterior cingulate and prefrontal cortex. **2015**, 132, 379-88	20

542	In Vivo Quantification of 5-HT2A Brain Receptors in Mdr1a KO Rats with 123I-R91150 Single-Photon Emission Computed Tomography. **2015**, 14,		5
541	GABAA receptor deficits predict recovery in patients with disorders of consciousness: A preliminary multimodal [(11) C]Flumazenil PET and fMRI study. **2015**, 36, 3867-77		6
540	Quantitative graphical analysis of simultaneous dynamic PET/MRI for assessment of prostate cancer. **2015**, 40, e236-40		9
539	Modeling clustered activity increase in amyloid-beta positron emission tomographic images with statistical descriptors. **2015**, 10, 759-70		4
538	Positron Emission Tomography (PET): Quantification and Kinetic Modeling. **2015**,		1
537	Quantitative amyloid imaging using image-derived arterial input function. **2015**, 10, e0122920		20
536	Novel Histone Deacetylase Class IIa Selective Substrate Radiotracers for PET Imaging of Epigenetic Regulation in the Brain. **2015**, 10, e0133512		16
535	Dissociable rate-dependent effects of oral methylphenidate on impulsivity and D2/3 receptor availability in the striatum. **2015**, 35, 3747-55		40
534	Improved factor analysis of dynamic PET images to estimate arterial input function and tissue curves. **2015**,		
533	Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. **2015**, 138, 2020-33		227
532	Low Dopamine D2/D3 Receptor Availability is Associated with Steep Discounting of Delayed Rewards in Methamphetamine Dependence. **2015**, 18, pyu119		47
531	Performance of 11C-Pittsburgh Compound B PET Binding Potential Images in the Detection of Amyloid Deposits on Equivocal Static Images. **2015**, 56, 1910-5		17
530	[(18)F]FPEB and [(18)F]FDEGPECO comparative study of mGlu5 quantification in rodent brain. **2015**, 98, 103-7		3
529	Automated reference region extraction and population-based input function for brain [(11)C]TMSX PET image analyses. *Journal of Cerebral Blood Flow and Metabolism*, **2015**, 35, 157-65	7.3	30
528	Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles. **2015**, 40, 755-65		36
527	Low amyloid-□deposition correlates with high education in cognitively normal older adults: a pilot study. **2015**, 30, 919-26		16
526	Test-retest reliability of (11)C-ORM-13070 in PET imaging of □2C-adrenoceptors in vivo in the human brain. **2015**, 42, 120-7		128
525	Chronic Back Pain Is Associated with Alterations in Dopamine Neurotransmission in the Ventral Striatum. **2015**, 35, 9957-65		94

524	Amyloid burden is associated with self-reported sleep in nondemented late middle-aged adults. **2015**, 36, 2568-76		129
523	Preclinical evaluation of a promising C-11 labeled PET tracer for imaging phosphodiesterase 10A in the brain of living subject. **2015**, 121, 253-62		15
522	Resting-state synchrony between the retrosplenial cortex and anterior medial cortical structures relates to memory complaints in subjective cognitive impairment. **2015**, 36, 2145-52		26
521	Methamphetamine-sensitized rats show augmented dopamine release to methylphenidate stimulation: a positron emission tomography using [18F]fallypride. **2015**, 232, 92-7		2
520	Endogenous Opioid Mechanisms Are Implicated in Obesity and Weight Loss in Humans. **2015**, 100, 3193-201		33
519	The simplified reference tissue model: model assumption violations and their impact on binding potential. *Journal of Cerebral Blood Flow and Metabolism*, **2015**, 35, 304-11	7.3	69
518	PET Quantification of Tau Pathology in Human Brain with 11C-PBB3. **2015**, 56, 1359-65		77
517	Quantification of [(11)C]PIB PET for imaging myelin in the human brain: a test-retest reproducibility study in high-resolution research tomography. *Journal of Cerebral Blood Flow and Metabolism*, **2015**, 35, 1771-82	7.3	43
516	Pharmacokinetic Modeling of Dynamic PET. **2015**, 209-215		
515	Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain. **2015**, 5, e549		79
514	The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study. **2015**, 36, 1736-1742		39
513	Radiosynthesis and in vivo evaluation of two imidazopyridineacetamides, [(11)C]CB184 and [(11)C]CB190, as a PET tracer for 18 kDa translocator protein: direct comparison with [(11)C](R)-PK11195. **2015**, 29, 325-35		16
512	Imaging pulmonary inducible nitric oxide synthase expression with PET. **2015**, 56, 76-81		29
511	Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. **2015**, 7, 8		27
510	Quantitative Evaluation of Tumor Early Response to a Vascular-Disrupting Agent with Dynamic PET. **2015**, 17, 865-73		4
509	Quantitative Analysis of -(E)-N-(3-Iodoprop-2-Enyl)-2-Carbofluoroethoxy-3-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease. **2015**, 56, 714-20		37
508	Characterization in humans of 18F-MNI-444, a PET radiotracer for brain adenosine 2A receptors. **2015**, 56, 586-91		38
507	No parkinsonism in SCA2 and SCA3 despite severe neurodegeneration of the dopaminergic substantia nigra. **2015**, 138, 3316-26		41

506	An exploratory efficacy study of the amyloid imaging agent [(18)F]flutemetamol in Japanese Subjects. **2015**, 29, 391-9		2
505	Immediate and Persistent Effects of Salvinorin A on the Kappa Opioid Receptor in Rodents, Monitored In Vivo with PET. **2015**, 40, 2865-72		13
504	Quantitative imaging of protein targets in the human brain with PET. **2015**, 60, R363-411		42
503	Imaging neuroinflammation in multiple sclerosis using TSPO-PET. **2015**, 3, 461-473		32
502	Clustering-initiated factor analysis application for tissue classification in dynamic brain positron emission tomography. *Journal of Cerebral Blood Flow and Metabolism*, **2015**, 35, 1104-11	7.3	2
501	Quantitative positron emission tomography of mGluR5 in rat brain with [(18) F]PSS232 at minimal invasiveness and reduced model complexity. **2015**, 133, 330-42		21
500	Quantification of blood flow-dependent component in estimates of beta-amyloid load obtained using quasi-steady-state standardized uptake value ratio. *Journal of Cerebral Blood Flow and Metabolism*, **2015**, 35, 1485-93	7.3	24
499	Quantitative kinetic analysis of PET amyloid imaging agents [(11)C]BF227 and [(18)F]FACT in human brain. **2015**, 42, 734-44		7
498	Parametric imaging and quantitative analysis of the PET amyloid ligand [(18)F]flutemetamol. **2015**, 121, 184-92		17
497	Amyloid binding in elderly subjects with declining or stable episodic memory function measured with PET and [C]AZD2184. **2015**, 42, 1507-11		4
496	Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging. **2014**, 18,		36
495	Non-exercise physical activity attenuates motor symptoms in Parkinson disease independent from nigrostriatal degeneration. **2015**, 21, 1227-31		11
494	Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging. **2015**, 60, R239-69		68
493	Quantification of Amyloidosis and rCBF with Dedicated PET, 7 T MR Imaging, and High-Resolution Microscopic MR Imaging at 16.4 T in APP23 Mice. **2015**, 56, 1593-9		9
492	FDG-PET Contributions to the Pathophysiology of Memory Impairment. **2015**, 25, 326-55		17
491	Human serotonin transporter availability predicts fear conditioning. **2015**, 98, 515-9		9
490	Noninvasive blood-free full quantification of positron emission tomography radioligand binding. *Journal of Cerebral Blood Flow and Metabolism*, **2015**, 35, 148-56	7.3	8
489	Partial volume correction in quantitative amyloid imaging. **2015**, 107, 55-64		138

488	Dynamic interactions between plasma IL-1 family cytokines and central endogenous opioid neurotransmitter function in humans. **2015**, 40, 554-65		18
487	Deficit in sustained attention following selective cholinergic lesion of the pedunculopontine tegmental nucleus in rat, as measured with both post-mortem immunocytochemistry and in vivo PET imaging with [□F]fluoroethoxybenzovesamicol. **2015**, 278, 107-14		24
486	Insulin resistance predicts brain amyloid deposition in late middle-aged adults. **2015**, 11, 504-510.e1		147
485	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. **2016**, 11, e0152082		31
484	Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer's Disease Patients Measured Using [18F] THK-5351. **2016**, 11, e0158460		65
483	Imaging Central Nervous System Demyelination and Remyelination by Positron-Emission Tomography. **2016**, 2, 93-98		5
482	Interpreting DTBZ binding data in rodent: Inherent variability and compensation. **2016**, 70, 147-52		5
481	High amyloid-□deposition related to depressive symptoms in older individuals with normal cognition: a pilot study. **2016**, 31, 920-8		31
480	Oral Abstracts. *Journal of Cerebral Blood Flow and Metabolism*, **2016**, 36, 1-173	7.3	4
479	Dopamine D1 signaling organizes network dynamics underlying working memory. **2016**, 2, e1501672		41
478	Comparison of [C]TZ1964B and [F]MNI659 for PET imaging brain PDE10A in nonhuman primates. **2016**, 4, e00253		4
477	PET Imaging of Tau Deposition in the Aging Human Brain. **2016**, 89, 971-982		619
476	Noninvasive evaluation of nicotinic acetylcholine receptor availability in mouse brain using single-photon emission computed tomography with [(123)I]5IA. **2016**, 43, 372-8		6
475	PET-CT and PET-MRI in Neurology. **2016**,		2
474	Modifiable Risk Factors and Brain Positron Emission Tomography Measures of Amyloid and Tau in Nondemented Adults with Memory Complaints. **2016**, 24, 729-37		38
473	Progressive Cortical Neuronal Damage and Chronic Hemodynamic Impairment in Atherosclerotic Major Cerebral Artery Disease. **2016**, 47, 1534-41		9
472	PET Imaging Study of S1PR1 Expression in a Rat Model of Multiple Sclerosis. **2016**, 18, 724-32		28
471	Positron Emission Tomography (PET) Use in Pharmacology. **2016**, 49-70		

470	Nicotine-specific and non-specific effects of cigarette smoking on endogenous opioid mechanisms. **2016**, 69, 69-77	23
469	Increased Seasonal Variation in Serotonin Transporter Binding in Seasonal Affective Disorder. **2016**, 41, 2447-54	26
468	Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease. **2016**, 139, 2275-89	48
467	Serotonin transporter binding is reduced in seasonal affective disorder following light therapy. **2016**, 134, 410-419	23
466	Impact of spillover from white matter by partial volume effect on quantification of amyloid deposition with [C]PiB PET. **2016**, 143, 316-324	23
465	Intranasal Opioid Administration in Rhesus Monkeys: PET Imaging and Antinociception. **2016**, 359, 366-373	18
464	Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases. **2016**, 73, 1334-1341	138
463	Dynamic Imaging of Individual Remyelination Profiles in Multiple Sclerosis. **2016**, 79, 726-738	101
462	Baseline symptom severity predicts serotonin transporter change during psychotherapy in patients with major depression. **2016**, 70, 34-41	6
461	In vivo quantifying molecular specificity of Cy5.5-labeled cyclic 9-mer peptide probe with dynamic fluorescence imaging. **2016**, 7, 1149-59	12
460	Positron Emission Tomography. **2016**, 99-117	
459	Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients. **2016**, 12, 41-6	14
458	Guidelines to PET measurements of the target occupancy in the brain for drug development. **2016**, 43, 2255-2262	18
457	Distinct roles for primate caudate dopamine D1 and D2 receptors in visual discrimination learning revealed using shRNA knockdown. **2016**, 6, 35809	10
456	Noninvasive bi-graphical analysis for the quantification of slowly reversible radioligand binding. **2016**, 61, 6770-6790	3
455	Endogenous opioidergic dysregulation of pain in fibromyalgia: a PET and fMRI study. **2016**, 157, 2217-2225	87
454	Comparative assessment of (18) F-Mefway as a serotonin 5-HT1A receptor PET imaging agent across species: Rodents, nonhuman primates, and humans. **2016**, 524, 1457-71	10
453	Parametric Binding Images of the TSPO Ligand 18F-DPA-714. **2016**, 57, 1543-1547	17

452	Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease. **2016**, 57, 1535-1542	72
451	Dopamine D2 receptor availability is linked to hippocampal-caudate functional connectivity and episodic memory. **2016**, 113, 7918-23	84
450	Investigation of Proposed Activity of Clarithromycin at GABAA Receptors Using [(11)C]Flumazenil PET. **2016**, 7, 746-50	3
449	Preclinical Characterization of the Phosphodiesterase 10A PET Tracer [(11)C]MK-8193. **2016**, 18, 579-87	10
448	Tracer Kinetic Analysis of (S)-[18F]-THK5117 as a PET Tracer for Assessing Tau Pathology. **2016**, 57, 574-81	41
447	PET Radioligands Reveal the Basis of Dementia in Parkinson's Disease and Dementia with Lewy Bodies. **2016**, 16, 118-24	32
446	Dynamic Changes in Striatal mGluR1 But Not mGluR5 during Pathological Progression of Parkinson's Disease in Human Alpha-Synuclein A53T Transgenic Rats: A Multi-PET Imaging Study. **2016**, 36, 375-84	24
445	Differential dopamine function in fibromyalgia. **2016**, 10, 829-39	31
444	In Vivo Imaging of Human Neuroinflammation. **2016**, 7, 470-83	121
443	Reduced sleep duration mediates decreases in striatal D2/D3 receptor availability in cocaine abusers. **2016**, 6, e752	26
442	Small-Animal PET Imaging of Tau Pathology with 18F-THK5117 in 2 Transgenic Mouse Models. **2016**, 57, 792-8	27
441	Diabetes, Gray Matter Loss, and Cognition in the Setting of Parkinson Disease. **2016**, 23, 577-81	18
440	The Role of Dopamine in Value-Based Attentional Orienting. **2016**, 26, 550-5	78
439	Socioeconomic status is associated with striatal dopamine D2/D3 receptors in healthy volunteers but not in cocaine abusers. **2016**, 617, 27-31	55
438	[18F]amyloid, hippocampal atrophy and their relation to longitudinal brain change in cognitively normal individuals. **2016**, 40, 173-180	22
437	Glial Activation and Glucose Metabolism in a Transgenic Amyloid Mouse Model: A Triple-Tracer PET Study. **2016**, 57, 954-60	86
436	Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias. **2016**, 86, 1152-8	60
435	Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. **2016**, 139, 1551-67	570

434	Optimal timing of [□H]Mefway PET for imaging the serotonin 1A receptor in healthy male subjects. **2016**, 107, 127-132		2
433	Overlapping expression of serotonin transporters and neurokinin-1 receptors in posttraumatic stress disorder: a multi-tracer PET study. **2016**, 21, 1400-7		16
432	P-Glycoprotein, not BCRP, Limits the Brain Uptake of [(18)F]Mefway in Rodent Brain. **2016**, 18, 267-73		4
431	Dual time-point imaging for post-dose binding potential estimation applied to a [C]raclopride PET dose occupancy study. *Journal of Cerebral Blood Flow and Metabolism*, **2017**, 37, 866-876	7.3	1
430	Quantitative longitudinal imaging of activated microglia as a marker of inflammation in the pilocarpine rat model of epilepsy using [C]-(R)-PK11195 PET and MRI. *Journal of Cerebral Blood Flow and Metabolism*, **2017**, 37, 1251-1263	7.3	19
429	Use of T1-weighted/T2-weighted magnetic resonance ratio to elucidate changes due to amyloid □ accumulation in cognitively normal subjects. **2017**, 13, 209-214		12
428	Neural correlates of apathy in late-life depression: a pilot [F]FDDNP positron emission tomography study. **2017**, 17, 186-193		18
427	Central □Opioidergic System Activation Evoked by Heavy and Severe-Intensity Cycling Exercise in Humans: a Pilot Study Using Positron Emission Tomography with 11C-Carfentanil. **2017**, 38, 19-26		13
426	Sensory Processing in Rhesus Monkeys: Developmental Continuity, Prenatal Treatment, and Genetic Influences. **2017**, 88, 183-197		5
425	Mutual effect of cerebral amyloid □and peripheral lymphocytes in cognitively normal older individuals. **2017**, 32, e93-e99		5
424	Binding of C-Pittsburgh compound-B correlated with white matter injury in hypertensive small vessel disease. **2017**, 31, 227-234		2
423	Initial Evaluation of an Adenosine A Receptor Ligand, C-Preladenant, in Healthy Human Subjects. **2017**, 58, 1464-1470		18
422	Neuroinflammation in Neurodegenerative Disorders-a Review. **2017**, 17, 25		155
421	Amyloid and tau PET demonstrate region-specific associations in normal older people. **2017**, 150, 191-199		49
420	GABA receptor subtypes in the mouse brain: Regional mapping and diazepam receptor occupancy by in vivo [F]flumazenil PET. **2017**, 150, 279-291		11
419	Dopamine in the medial amygdala network mediates human bonding. **2017**, 114, 2361-2366		68
418	New Repeat Polymorphism in the Gene Predicts Striatal Dopamine D2/D3 Receptor Availability and Stimulant-Induced Dopamine Release in the Healthy Human Brain. **2017**, 37, 4982-4991		13
417	Progressive Cortical Neuronal Damage and Extracranial-Intracranial Bypass Surgery in Patients with Misery Perfusion. **2017**, 38, 935-941		4

416	Neuroimaging markers associated with maintenance of optimal memory performance in late-life. **2017**, 100, 164-170	23
415	Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis. **2017**, 23, 1469-1478	17
414	C-PBR28 and F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis. **2017**, 58, 1477-1482	36
413	Dopamine D2/D3 imbalance during migraine attack and allodynia in vivo. **2017**, 88, 1634-1641	30
412	Density of available striatal dopamine receptors predicts trait impulsiveness during performance of an attention-demanding task. **2017**, 118, 64-68	4
411	In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings. **2017**, 36, 50-63	84
410	Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. **2017**, 16, 351-359	64
409	Generalized paired-agent kinetic model for in vivo quantification of cancer cell-surface receptors under receptor saturation conditions. **2017**, 62, 394-414	6
408	A single-scan protocol for absolute D receptor quantification with [I]IBZM SPECT. **2017**, 147, 461-472	10
407	In vivo evaluation of [F]FECIMBI-36, an agonist 5-HT receptor PET radioligand in nonhuman primate. **2017**, 27, 21-23	10
406	. **2017**, 1, 128-135	3
405	Utility of Molecular and Structural Brain Imaging to Predict Progression from Mild Cognitive Impairment to Dementia. **2017**, 60, 939-947	4
404	Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis. **2017**, 140, 2927-2938	57
403	Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model. **2017**, 548, 592-596	364
402	Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: Implications for anhedonia, anxiety and treatment response. **2017**, 27, 977-986	41
401	Early synaptic dysfunction induced by □synuclein in a rat model of Parkinson's disease. **2017**, 7, 6363	43
400	In Vivo Monitoring for Regional Changes of Metabotropic Glutamate Receptor Subtype 1 (mGluR1) in Pilocarpine-Induced Epileptic Rat Brain by Small-Animal PET. **2017**, 7, 14945	7
399	Whole-body biodistribution and the influence of body activity on brain kinetic analysis of the C-PiB PET scan. **2017**, 10, 464-474	

398	Striatal Dopamine D2/D3 Receptor Availability Varies Across Smoking Status. **2017**, 42, 2325-2332	19
397	Quantitative positron emission tomography in brain research. **2017**, 1670, 220-234	27
396	Associations between cerebral amyloid and changes in cognitive function and falls risk in subcortical ischemic vascular cognitive impairment. **2017**, 17, 133	3
395	Compartmental Modeling in PET Kinetics. **2017**, 323-352	
394	In Vivo Comparison of Tau Radioligands F-THK-5351 and F-THK-5317. **2017**, 58, 996-1002	43
393	Estimation of the binding potential BP without a reference region or blood samples for brain PET studies. **2017**, 146, 121-131	7
392	Preclinical in vivo and in vitro comparison of the translocator protein PET ligands [F]PBR102 and [F]PBR111. **2017**, 44, 296-307	17
391	Modeling Strategies for Quantification of In Vivo F-AV-1451 Binding in Patients with Tau Pathology. **2017**, 58, 623-631	46
390	Characterization of [C]Lu AE92686 as a PET radioligand for phosphodiesterase 10A in the nonhuman primate brain. **2017**, 44, 308-320	4
389	Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging. **2017**, 58, 332-338	66
388	Assessing neuronal density in peri-infarct cortex with PET: Effects of cortical topology and partial volume correction. **2017**, 38, 326-338	7
387	Pharmacokinetic Evaluation of the Tau PET Radiotracer F-T807 (F-AV-1451) in Human Subjects. **2017**, 58, 484-491	65
386	Longitudinal Small-Animal PET Imaging of the zQ175 Mouse Model of Huntington Disease Shows In Vivo Changes of Molecular Targets in the Striatum and Cerebral Cortex. **2017**, 58, 617-622	18
385	TSPO imaging using the novel PET ligand [F]GE-180: quantification approaches in patients with multiple sclerosis. **2017**, 7, 89	40
384	Parametric PET Image Reconstruction via Regional Spatial Bases and Pharmacokinetic Time Activity Model. **2017**, 19, 629	1
383	Revisiting the Logan plot to account for non-negligible blood volume in brain tissue. **2017**, 7, 66	7
382	In Vivo Characterization of Two F-Labeled PDE10A PET Radioligands in Nonhuman Primate Brains. **2018**, 9, 1066-1073	3
381	Reference tissue models in the assessment of C-DTBZ binding to the VMAT2 in rat striatum: A test-retest reproducibility study. **2018**, 72, e22029	4

380	Serotonin, β-amyloid, and cognition in Parkinson disease. **2018**, 83, 994-1002	27
379	Brain morphology, cognition, and β-amyloid in older adults with superior memory performance. **2018**, 67, 162-170	35
378	β-Amyloid accumulation in the human brain after one night of sleep deprivation. **2018**, 115, 4483-4488	333
377	Nigrostriatal proteasome inhibition impairs dopamine neurotransmission and motor function in minipigs. **2018**, 303, 142-152	20
376	Chronic Δ9-THC in Rhesus Monkeys: Effects on Cognitive Performance and Dopamine D2/D3 Receptor Availability. **2018**, 364, 300-310	10
375	Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease. **2018**, 14, 652-663	11
374	Imaging Aβ and tau in early stage Alzheimer's disease with [F]AV45 and [F]AV1451. **2018**, 8, 19	10
373	Characterization of 3 Novel Tau Radiopharmaceuticals, C-RO-963, C-RO-643, and F-RO-948, in Healthy Controls and in Alzheimer Subjects. **2018**, 59, 1869-1876	61
372	Cardiovascular Risk Factor Burden in Veterans and Non-Veterans with Parkinson Disease. **2018**, 8, 153-160	5
371	Vascular-metabolic and GABAergic Inhibitory Correlates of Neural Variability Modulation. A Combined fMRI and PET Study. **2018**, 379, 142-151	3
370	D2/D3 dopamine receptor binding with [F-18]fallypride correlates of executive function in medication-naïve patients with schizophrenia. **2018**, 192, 442-456	12
369	Parametric Imaging of [C]Flumazenil Binding in the Rat Brain. **2018**, 20, 114-123	4
368	Novel F-Labeled κ-Opioid Receptor Antagonist as PET Radiotracer: Synthesis and In Vivo Evaluation of F-LY2459989 in Nonhuman Primates. **2018**, 59, 140-146	22
367	Latent-Profile Analysis Reveals Behavioral and Brain Correlates of Dopamine-Cognition Associations. **2018**, 28, 3894-3907	22
366	Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease. **2018**, 17, 452-464	83
365	Pseudoreference Regions for Glial Imaging with C-PBR28: Investigation in 2 Clinical Cohorts. **2018**, 59, 107-114	26
364	In Vivo Brain Plaque and Tangle Burden Mediates the Association Between Diastolic Blood Pressure and Cognitive Functioning in Nondemented Adults. **2018**, 26, 13-22	4
363	Human brain imaging of nicotinic acetylcholine α4β2* receptors using [F]Nifene: Selectivity, functional activity, toxicity, aging effects, gender effects, and extrathalamic pathways. **2018**, 526, 80-95	14

362	Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial. **2018**, 26, 266-277	126
361	Associations Between Tau, Amyloid, and Cognition in Parkinson Disease. **2018**, 75, 227-235	36
360	Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging. **2018**, 38, 530-543	126
359	A first-in-man PET study of [F]PSS232, a fluorinated ABP688 derivative for imaging metabotropic glutamate receptor subtype 5. **2018**, 45, 1041-1051	12
358	Association of genetic ancestry with striatal dopamine D2/D3 receptor availability. **2018**, 23, 1711-1716	14
357	Adaptive Weighted Nonlinear Least Squares Method for Fluorodeoxyglucose Positron Emission Tomography Quantification. **2018**, 38, 63-75	2
356	Dopamine transporter imaging with [F]FE-PE2I PET and [I]FP-CIT SPECT-a clinical comparison. **2018**, 8, 100	32
355	Reproducible quantification of cardiac sympathetic innervation using graphical modeling of carbon-11-meta-hydroxyephedrine kinetics with dynamic PET-CT imaging. **2018**, 8, 63	7
354	Association between aromatase in human brains and personality traits. **2018**, 8, 16841	10
353	Quantification of Contrast Kinetics in Clinical Imaging. **2018**,	1
352	Longer TOMM40 poly-T variants associated with higher FDDNP-PET medial temporal tau and amyloid binding. **2018**, 13, e0208358	3
351	Comparison of two different methods of image analysis for the assessment of microglial activation in patients with multiple sclerosis using (R)-[N-methyl-carbon-11]PK11195. **2018**, 13, e0201289	6
350	Advances in PET Methodology. **2018**, 141, 3-30	3
349	Imaging biomarkers of behavioral impairments: A pilot micro-positron emission tomographic study in a rat electrical post-status epilepticus model. **2018**, 59, 2194-2205	12
348	Habitual exercisers versus sedentary subjects with Parkinson's Disease: Multimodal PET and fMRI study. **2018**, 33, 1945-1950	18
347	Investigation of the quantitative accuracy of low-dose amyloid and tau PET imaging. **2018**, 11, 451-459	0
346	Validation of diffusion tensor imaging measures of nigrostriatal neurons in macaques. **2018**, 13, e0202201	9
345	Dynamic image denoising for voxel-wise quantification with Statistical Parametric Mapping in molecular neuroimaging. **2018**, 13, e0203589	4

344	Tracer Kinetics in Radionanomedicine. **2018**, 293-310	
343	Dual tracer tau PET imaging reveals different molecular targets for C-THK5351 and C-PBB3 in the Alzheimer brain. **2018**, 45, 1605-1617	27
342	Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. **2018**, 19, 406-416	37
341	Early Detection of A Deposition in the 5xFAD Mouse by Amyloid PET. **2018**, 2018, 5272014	13
340	Imaging correlates of behavioral impairments: An experimental PET study in the rat pilocarpine epilepsy model. **2018**, 118, 9-21	15
339	PBB3 binding in a patient with corticobasal syndrome. **2018**, 33, 1359-1360	5
338	FDDNP-PET Tau Brain Protein Binding Patterns in Military Personnel with Suspected Chronic Traumatic Encephalopathy1. **2018**, 65, 79-88	10
337	Investigation of the influence of sampling schemes on quantitative dynamic fluorescence imaging. **2018**, 9, 1859-1870	3
336	The Impact of Preprocessing Pipeline Choice in Univariate and Multivariate Analyses of PET Data. **2018**,	1
335	Molecular Imaging of Sirtuin1 Expression-Activity in Rat Brain Using Positron-Emission Tomography-Magnetic-Resonance Imaging with [F]-2-Fluorobenzoylaminohexanoicanilide. **2018**, 61, 7116-7130	2
334	Methylation of the dopamine transporter gene in blood is associated with striatal dopamine transporter availability in ADHD: A preliminary study. **2018**, 48, 1884-1895	17
333	Self-rated intensity of habitual physical activities is positively associated with dopamine D receptor availability and cognition. **2018**, 181, 605-616	13
332	In vivo quantification of neurofibrillary tangles with [F]MK-6240. **2018**, 10, 74	69
331	In vivo quantification of glial activation in minipigs overexpressing human □synuclein. **2018**, 72, e22060	9
330	The correlation between striatal and cortical binding ratio of C-PiB-PET in amyloid-uptake-positive patients. **2018**, 32, 398-403	5
329	Noninvasive PK11195-PET Image Analysis Techniques Can Detect Abnormal Cerebral Microglial Activation in Parkinson's Disease. **2018**, 28, 496-505	17
328	Selective D2 receptor PET in manganese-exposed workers. **2018**, 91, e1022-e1030	23
327	Evaluation of F-RO-948 PET for Quantitative Assessment of Tau Accumulation in the Human Brain. **2018**, 59, 1877-1884	44

326	Imaging Brain Metabolism in the Newborn. **2018**, 33, 851-860		15
325	Are dopamine receptor and transporter changes in Rett syndrome reflected in Mecp2-deficient mice?. **2018**, 307, 74-81		11
324	Reduced striatal dopamine release during motor skill acquisition in Parkinson's disease. **2018**, 13, e0196661		6
323	Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles. **2019**, 60, 107-114		63
322	Regional times to equilibria and their impact on semi-quantification of [F]AV-1451 uptake. *Journal of Cerebral Blood Flow and Metabolism*, **2019**, 39, 2223-2232	7.3	5
321	In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls. **2019**, 60, 93-99		106
320	QModeling: a Multiplatform, Easy-to-Use and Open-Source Toolbox for PET Kinetic Analysis. **2019**, 17, 103-114		2
319	Quantifying SV2A density and drug occupancy in the human brain using [C]UCB-J PET imaging and subcortical white matter as reference tissue. **2019**, 46, 396-406		45
318	Spatially Adaptive Varying Correlation Analysis for Multimodal Neuroimaging Data. **2019**, 38, 113-123		2
317	The Value of In Vitro Binding as Predictor of In Vivo Results: A Case for [F]FDDNP PET. **2019**, 21, 25-34		7
316	Essentials of Quantitative Imaging with PET. **2019**, 219-233		1
315	Optimized dual-time-window protocols for quantitative [F]flutemetamol and [F]florbetaben PET studies. **2019**, 9, 32		19
314	Amyloid deposition in subcortical stroke patients and effects of educational achievement: A pilot study. **2019**, 34, 1651-1657		6
313	Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [F]MK6240 in human subjects. **2019**, 46, 2099-2111		13
312	The Influence of Hippocampal Dopamine D2 Receptors on Episodic Memory Is Modulated by and Polymorphisms. **2019**, 31, 1422-1429		2
311	Impact of chronic migraine attacks and their severity on the endogenous opioid neurotransmission in the limbic system. **2019**, 23, 101905		11
310	Multi-Modal Signatures of Tau Pathology, Neuronal Fiber Integrity, and Functional Connectivity in Traumatic Brain Injury. **2019**, 36, 3233-3243		16
309	Tau deposition is associated with functional isolation of the hippocampus in aging. **2019**, 10, 4900		39

308	Exercise increases caudate dopamine release and ventral striatal activation in Parkinson's disease. **2019**, 34, 1891-1900	41
307	PET Measures of D1, D2, and DAT Binding Are Associated With Heightened Tactile Responsivity in Rhesus Macaques: Implications for Sensory Processing Disorder. **2019**, 13, 29	1
306	Cardiovascular factors are related to dopamine integrity and cognition in aging. **2019**, 6, 2291-2303	5
305	AD molecular: Imaging tau aggregates with positron emissions tomography. **2019**, 165, 107-138	7
304	Mapping the landscape of human dopamine D2/3 receptors with [C]raclopride. **2019**, 224, 2871-2882	15
303	A pitfall of white matter reference regions used in [F] florbetapir PET: a consideration of kinetics. **2019**, 33, 848-854	6
302	μ-Opioid Activity in Chronic TMD Pain Is Associated with COMT Polymorphism. **2019**, 98, 1324-1331	8
301	Predicting PET-derived demyelination from multimodal MRI using sketcher-refiner adversarial training for multiple sclerosis. **2019**, 58, 101546	17
300	Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [F]THK5317 PET. **2019**, 22, 101681	2
299	Accuracy and reliability of [C]PBR28 specific binding estimated without the use of a reference region. **2019**, 188, 102-110	16
298	Sleep as a Potential Biomarker of Tau and Amyloid Burden in the Human Brain. **2019**, 39, 6315-6324	70
297	Human Positron Emission Tomography Neuroimaging. **2019**, 21, 551-581	24
296	Optimization of preprocessing strategies in Positron Emission Tomography (PET) neuroimaging: A [C]DASB PET study. **2019**, 199, 466-479	12
295	Alzheimer's pathology targets distinct memory networks in the ageing brain. **2019**, 142, 2492-2509	56
294	Selective neuronal damage and blood pressure in atherosclerotic major cerebral artery disease. **2019**, 90, 975-980	2
293	Network Patterns of Beta-Amyloid Deposition in Parkinson's Disease. **2019**, 56, 7731-7740	9
292	Tau covariance patterns in Alzheimer's disease patients match intrinsic connectivity networks in the healthy brain. **2019**, 23, 101848	39
291	Kinetic Modeling of Radiotracers. **2019**, 501-514	1

290	Misery perfusion and amyloid deposition in atherosclerotic major cerebral artery disease. **2019**, 22, 101762		4
289	Molecular imaging HDACs class IIa expression-activity and pharmacologic inhibition in intracerebral glioma models in rats using PET/CT/(MRI) with [F]TFAHA. **2019**, 9, 3595		16
288	Effect of Off-Target Binding on F-Flortaucipir Variability in Healthy Controls Across the Life Span. **2019**, 60, 1444-1451		49
287	Cognitive Control as a 5-HT-Based Domain That Is Disrupted in Major Depressive Disorder. **2019**, 10, 691		11
286	Expectation effects on brain dopamine responses to methylphenidate in cocaine use disorder. **2019**, 9, 93		12
285	Measuring longitudinal cognition: Individual tests versus composites. **2019**, 11, 74-84		27
284	Imaging metabotropic glutamate receptor system: Application of positron emission tomography technology in drug development. **2019**, 39, 1892-1922		9
283	Vascular Burden Score Impacts Cognition Independent of Amyloid PET and MRI Measures of Alzheimer's Disease and Vascular Brain Injury. **2019**, 68, 187-196		14
282	Sucrose intake lowers Ebpioid and dopamine D2/3 receptor availability in porcine brain. **2019**, 9, 16918		13
281	Positron emission tomography probes targeting bromodomain and extra-terminal (BET) domains to enable in vivo neuroepigenetic imaging. **2019**, 55, 12932-12935		11
280	Expression and co-expression of serotonin and dopamine transporters in social anxiety disorder: a multitracer positron emission tomography study. **2021**, 26, 3970-3979		21
279	Reduced acquisition time PET pharmacokinetic modelling using simultaneous ASL-MRI: proof of concept. *Journal of Cerebral Blood Flow and Metabolism*, **2019**, 39, 2419-2432	7.3	7
278	Discrepancies in Kappa Opioid Agonist Binding Revealed through PET Imaging. **2019**, 10, 384-395		16
277	Dorsal striatal dopamine D1 receptor availability predicts an instrumental bias in action learning. **2019**, 116, 261-270		21
276	Longitudinal tau accumulation and atrophy in aging and alzheimer disease. **2019**, 85, 229-240		116
275	C957T-mediated Variation in Ligand Affinity Affects the Association between C-raclopride Binding Potential and Cognition. **2019**, 31, 314-325		11
274	Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease. **2019**, 46, 1152-1163		23
273	A non-human primate model for stable chronic Parkinson's disease induced by MPTP administration based on individual behavioral quantification. **2019**, 311, 277-287		19

272	Rhesus Macaque Brain Atlas Regions Aligned to an MRI Template. **2019**, 17, 295-306		7
271	Quantitative PET Imaging in Drug Development: Estimation of Target Occupancy. **2019**, 81, 3508-3541		10
270	Cerebral serotonin transporter measurements with [C]DASB: A review on acquisition and preprocessing across 21 PET centres. *Journal of Cerebral Blood Flow and Metabolism*, **2019**, 39, 210-222	7.3	21
269	Dopamine receptor density and white mater integrity: F-fallypride positron emission tomography and diffusion tensor imaging study in healthy and schizophrenia subjects. **2020**, 14, 736-752		8
268	Validation of Parametric Methods for [C]UCB-J PET Imaging Using Subcortical White Matter as Reference Tissue. **2020**, 22, 444-452		15
267	Quantitative parametric maps of O-(2-[F]fluoroethyl)-L-tyrosine kinetics in diffuse glioma. *Journal of Cerebral Blood Flow and Metabolism*, **2020**, 40, 895-903	7.3	4
266	Simultaneous Covariance Inference for Multimodal Integrative Analysis. **2020**, 115, 1279-1291		3
265	Parametric Imaging With PET and SPECT. **2020**, 4, 1-23		25
264	Parametric methods for [F]flortaucipir PET. *Journal of Cerebral Blood Flow and Metabolism*, **2020**, 40, 365-373	7.3	11
263	F-FIBT may expand PET for amyloid imaging in neurodegenerative diseases. **2020**, 25, 2608-2619		7
262	High long-term test-retest reliability for extrastriatal C-raclopride binding in healthy older adults. *Journal of Cerebral Blood Flow and Metabolism*, **2020**, 40, 1859-1868	7.3	6
261	Different preprocessing strategies lead to different conclusions: A [C]DASB-PET reproducibility study. *Journal of Cerebral Blood Flow and Metabolism*, **2020**, 40, 1902-1911	7.3	2
260	Test-retest repeatability of [F]Flortaucipir PET in Alzheimer's disease and cognitively normal individuals. *Journal of Cerebral Blood Flow and Metabolism*, **2020**, 40, 2464-2474	7.3	13
259	Positive association between cerebral grey matter metabolism and dopamine D/D receptor availability in healthy and schizophrenia subjects: An F-fluorodeoxyglucose and F-fallypride positron emission tomography study. **2020**, 21, 368-382		7
258	Head-to-head comparison of tau positron emission tomography tracers [F]flortaucipir and [F]RO948. **2020**, 47, 342-354		33
257	The pro-psychotic metabotropic glutamate receptor compounds fenobam and AZD9272 share binding sites with monoamine oxidase-B inhibitors in humans. **2020**, 162, 107809		7
256	PET Imaging of Pancreatic Dopamine D and D Receptor Density with C-(+)-PHNO in Type 1 Diabetes. **2020**, 61, 570-576		11
255	[F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis. **2020**, 47, 366-378		6

254	Balance between Transmitter Availability and Dopamine D2 Receptors in Prefrontal Cortex Influences Memory Functioning. **2020**, 30, 989-1000		14
253	Image-based biomedical data modeling and parametric imaging. **2020**, 461-521		
252	Repurposing radiotracers for myelin imaging: a study comparing 18F-florbetaben, 18F-florbetapir, 18F-flutemetamol,11C-MeDAS, and 11C-PiB. **2020**, 47, 490-501		16
251	Cholinergic denervation in patients with idiopathic rapid eye movement sleep behaviour disorder. **2020**, 27, 644-652		12
250	Molecular imaging in biology and pharmacology. **2020**, 523-560		
249	Spatial patterns of tau deposition are associated with amyloid, ApoE, sex, and cognitive decline in older adults. **2020**, 47, 2155-2164		5
248	Breast Cancer F-ISO-1 Uptake as a Marker of Proliferation Status. **2020**, 61, 665-670		15
247	Automatic delineation algorithm of reference region for amyloid imaging based on kinetics. **2020**, 34, 102-107		2
246	Ethnic disparities in pain processing among healthy adults: Ebpioid receptor binding potential as a putative mechanism. **2020**, 161, 810-820		6
245	[11C]dihydrotetrabenazine Positron Emission Tomography in Manganese-Exposed Workers. **2020**, 62, 788-794		3
244	Proper names from story recall are associated with beta-amyloid in cognitively unimpaired adults at risk for Alzheimer's disease. **2020**, 131, 137-150		8
243	Predicting PET-derived myelin content from multisequence MRI for individual longitudinal analysis in multiple sclerosis. **2020**, 223, 117308		9
242	Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease. **2020**, 8, 196		4
241	False positive rates in positron emission tomography (PET) voxelwise analyses. *Journal of Cerebral Blood Flow and Metabolism*, **2021**, 41, 1647-1657	7.3	4
240	Cortical cholinergic dysfunction correlates with microglial activation in the substantia innominata in REM sleep behavior disorder. **2020**, 81, 89-93		6
239	Identification and Development of a New Positron Emission Tomography Ligand 4-(2-Fluoro-4-[C]methoxyphenyl)-5-((1-methyl-1-pyrazol-3-yl)methoxy)picolinamide for Imaging Metabotropic Glutamate Receptor Subtype 2 (mGlu). **2020**, 63, 11469-11483		2
238	Evaluation of the neuroprotective effect of taurine in Alzheimer's disease using functional molecular imaging. **2020**, 10, 15551		4
237	Quantification of aromatase binding in the female human brain using [C]cetrozole positron emission tomography. **2020**, 98, 2208-2218		2

236	Sleep Disturbance Forecasts Amyloid Accumulation across Subsequent Years. **2020**, 30, 4291-4298.e3	36
235	PET Imaging of Mitochondrial Function in the Living Brain. **2020**,	1
234	Reduced Expression of Cerebral Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome. **2020**, 10,	8
233	ADORA2A variation and adenosine A receptor availability in the human brain with a focus on anxiety-related brain regions: modulation by ADORA1 variation. **2020**, 10, 406	3
232	Noninvasive Measurement of [C]PiB Distribution Volume Using Integrated PET/MRI. **2020**, 10,	1
231	Distinct effects of beta-amyloid and tau on cortical thickness in cognitively healthy older adults. **2021**, 17, 1085-1096	8
230	A Multi-Ligand Imaging Study Exploring GABAergic Receptor Expression and Inflammation in Multiple Sclerosis. **2020**, 22, 1600-1608	2
229	Corticostriatal White Matter Integrity and Dopamine D1 Receptor Availability Predict Age Differences in Prefrontal Value Signaling during Reward Learning. **2020**, 30, 5270-5280	2
228	Neurophysiological Biomarkers of Parkinson's Disease. **2020**, 10, 471-480	9
227	Clinical evaluation of [F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease. **2020**, 47, 3176-3185	10
226	PET technology for drug development in psychiatry. **2020**, 40, 114-121	9
225	Neurophysiological signatures in Alzheimer's disease are distinctly associated with TAU, amyloid- accumulation, and cognitive decline. **2020**, 12,	28
224	The Effects of Intramuscular Naloxone Dose on Mu Receptor Displacement of Carfentanil in Rhesus Monkeys. **2020**, 25,	4
223	Evaluation of the Neuroprotective Effect of Microglial Depletion by CSF-1R Inhibition in a Parkinson's Animal Model. **2020**, 22, 1031-1042	8
222	A strategy to account for noise in the X-variable to reduce underestimation in Logan graphical analysis for quantifying receptor density in positron emission tomography. **2020**, 20, 15	2
221	Deep Brain Stimulation of the Medial Forebrain Bundle in a Rodent Model of Depression: Exploring Dopaminergic Mechanisms with Raclopride and Micro-PET. **2020**, 98, 8-20	6
220	Visualization of AMPA receptors in living human brain with positron emission tomography. **2020**, 26, 281-288	24
219	Characterization of F-PM-PBB3 (F-APN-1607) Uptake in the rTg4510 Mouse Model of Tauopathy. **2020**, 25,	12

218	Repeatability of parametric methods for [F]florbetapir imaging in Alzheimer's disease and healthy controls: A test-retest study. *Journal of Cerebral Blood Flow and Metabolism*, **2021**, 41, 569-578	7.3	3
217	Simulating the effect of cerebral blood flow changes on regional quantification of [F]flutemetamol and [F]florbetaben studies. *Journal of Cerebral Blood Flow and Metabolism*, **2021**, 41, 579-589	7.3	7
216	Chemokine Receptor 2-targeted Molecular Imaging in Pulmonary Fibrosis. A Clinical Trial. **2021**, 203, 78-89		15
215	Brain 5-HT1A Receptor Binding in Multiple System Atrophy: An [F]-MPPF PET Study. **2021**, 36, 246-251		4
214	Regional Tau Effects on Prospective Cognitive Change in Cognitively Normal Older Adults. **2021**, 41, 366-375		7
213	Analysis of Four-Dimensional Data for Total Body PET Imaging. **2021**, 16, 55-64		1
212	Kinetic Modelling and Test-Retest Reproducibility for the Dopamine DR Radioligand [C]SCH23390 in Healthy and Diseased Mice. **2021**, 23, 208-219		3
211	Quantification of SV2A Binding in Rodent Brain Using [F]SynVesT-1 and PET Imaging. **2021**, 23, 372-381		6
210	Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia. **2021**, 36, 389-397		6
209	Dopaminergic Nigrostriatal Connectivity in Early Parkinson Disease: In Vivo Neuroimaging Study of C-DTBZ PET Combined with Correlational Tractography. **2021**, 62, 545-552		7
208	New PET radiopharmaceuticals for imaging CNS diseases. **2021**,		
207	Pharmacokinetic Modeling. **2021**, 1625-1631		0
206	Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals. **2021**, 13, e12216		1
205	Optimized Methodology for Reference Region and Image-Derived Input Function Kinetic Modeling in Preclinical PET. **2021**, 1-1		0
204	Preliminary Investigation of a Novel 18F Radiopharmaceutical for Imaging CB2 Receptors in a SOD Mouse Model. **2021**, 74, 443		2
203	Pharmacokinetic neuroimaging to study the dose-related brain kinetics and target engagement of buprenorphine in vivo. **2021**, 46, 1220-1228		1
202	PET imaging reveals early and progressive dopaminergic deficits after intra-striatal injection of preformed alpha-synuclein fibrils in rats. **2021**, 149, 105229		14
201	Spatially constrained kinetic modeling with dual reference tissues improves F-flortaucipir PET in studies of Alzheimer disease. **2021**, 48, 3172-3186		1

200	Association of Memory Impairment With Concomitant Tau Pathology in Patients With Cerebral Amyloid Angiopathy. **2021**, 96, e1975-e1986		2
199	Molecular Imaging Approaches in Dementia. **2021**, 298, 517-530		8
198	Uses of Human MR and PET Imaging in Research of Neurodegenerative Brain Diseases. **2021**, 18, 661-672		1
197	Improving contrast between gray and white matter of Logan graphical analysis' parametric images in positron emission tomography through least-squares cubic regression and principal component analysis. **2021**,		2
196	Dopaminergic Regulation of Reward System Connectivity Underpins Pain and Emotional Suffering in Migraine. **2021**, 14, 631-643		3
195	Principal Component Analysis of Striatal and Extrastriatal D2 Dopamine Receptor Positron Emission Tomography in Manganese-Exposed Workers. **2021**, 182, 132-141		1
194	Kinetic and static analysis of poly-(adenosine diphosphate-ribose) polymerase-1 (PARP-1) targeted F-FluorThanatrace (F-FTT) PET images of ovarian cancer. **2021**,		3
193	Strategies to reduce sample sizes in Alzheimer's disease primary and secondary prevention trials using longitudinal amyloid PET imaging. **2021**, 13, 82		3
192	Reproducibility of findings in modern PET neuroimaging: insight from the NRM2018 grand challenge. *Journal of Cerebral Blood Flow and Metabolism*, **2021**, 41, 2778-2796	7.3	4
191	A high-resolution in vivo atlas of the human brain's benzodiazepine binding site of GABA receptors. **2021**, 232, 117878		10
190	Alzheimer's Pathology Is Associated with Dedifferentiation of Intrinsic Functional Memory Networks in Aging. **2021**, 31, 4781-4793		4
189	Parametric imaging of dual-time window [F]flutemetamol and [F]florbetaben studies. **2021**, 234, 117953		2
188	Longitudinal change in TSPO PET imaging in progressive multiple sclerosis. **2021**, 8, 1755-1759		2
187	F-florbetapir PET/MRI for quantitatively monitoring myelin loss and recovery in patients with multiple sclerosis: A longitudinal study. **2021**, 37, 100982		0
186	Astrocyte activation imaging with 11C-acetate and amyloid PET in mild cognitive impairment due to Alzheimer pathology. **2021**, 42, 1261-1269		3
185	Preclinical and clinical study on [F]DRKXH1: a novel β-amyloid PET tracer for Alzheimer's disease. **2021**, 1		4
184	Striatal acetylcholine-dopamine imbalance in Parkinson's disease: in vivo neuroimaging study with dual-tracer PET and dopaminergic PET-informed correlational tractography. **2021**,		3
183	Tau and β-Amyloid Burden Predict Actigraphy-Measured and Self-Reported Impairment and Misperception of Human Sleep. **2021**, 41, 7687-7696		4

182	Evaluation of [F]-JNJ-64326067-AAA tau PET tracer in humans. *Journal of Cerebral Blood Flow and Metabolism*, **2021**, 41, 3302-3313	7.3	3
181	Molecular imaging of the serotonin transporter availability and occupancy by antidepressant treatment in late-life depression. **2021**, 194, 108447		2
180	Different Alterations of Agonist and Antagonist Binding to 5-HT1A Receptor in a Rat Model of Parkinson's Disease and Levodopa-Induced Dyskinesia: A MicroPET Study. **2021**, 11, 1257-1269		1
179	Sex differences in dopamine integrity and brain structure among healthy older adults: Relationships to episodic memory. **2021**, 105, 272-279		1
178	Positron emission tomography imaging of serotonin degeneration and beta-amyloid deposition in late-life depression evaluated with multi-modal partial least squares. **2021**, 11, 473		0
177	Test-retest reproducibility of cerebral adenosine A receptor quantification using [C]preladenant. **2021**, 1		
176	Rapid high-quality PET Patlak parametric image generation based on direct reconstruction and temporal nonlocal neural network. **2021**, 240, 118380		1
175	Dopamine release during psychological stress in euthymic bipolar I disorder: a Positron Emission Tomography study with [C]raclopride. **2021**, 295, 724-732		
174	Concepts for design and analysis of receptor radiopharmaceuticals: The Receptor-Binding Radiotracers series of meetings provided the foundation. **2021**, 92, 5-23		2
173	4D deep image prior: dynamic PET image denoising using an unsupervised four-dimensional branch convolutional neural network. **2021**, 66, 015006		18
172	Tau aggregation and increased neuroinflammation in athletes after sports-related concussions and in traumatic brain injury patients - A PET/MR study. **2021**, 30, 102665		5
171	Tracer Kinetic Modeling: Basics and Concepts. **2021**, 531-549		
170	Quantification of Tau Load in Alzheimer's Disease Clinical Trials Using Positron Emission Tomography. **2018**, 1750, 221-229		1
169	Quantitative approaches to amyloid imaging. **2011**, 680, 201-25		3
168	Exact Parameter Determination for Parkinson's Disease Diagnosis with PET Using an Algebraic Approach. **2007**, 110-124		3
167	Compartmental Modeling in Emission Tomography. **2012**, 1065-1081		1
166	Ligand Tracer Kinetics: Theory and Application. **2004**, 75-93		4
165	Serotonin Synthesis Studied with Positron Emission Tomography (PET). **2014**, 687-709		1

164	Limitations of Binding Potential as a Measure of Receptor Function: A Two-Point Correction for the Effects of Mass. **1998**, 407-413		2
163	Estimation of Binding Potential for the 5HT2 Receptor Ligand [18F]Setoperone by a Noninvasive Reference Region Graphical Method. **1998**, 421-426		1
162	Effect of Population k2 Values in Graphical Estimation of DV Ratios of Reversible Ligands. **2001**, 127-129		2
161	Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. **2017**, 157, 448-463		228
160	Conscientiousness is associated with less amyloid deposition in cognitively normal aging. **2020**, 35, 993-999		2
159	Positron Emission Tomography Compartmental Models: A Basis Pursuit Strategy for Kinetic Modeling. *Journal of Cerebral Blood Flow and Metabolism*, **2002**, 1425-1439	7.3	73
158	In Vivo Measurement of Receptor Density and Affinity: Comparison of the Routine Sequential Method With a Nonsequential Method in Studies of Dopamine D2 Receptors With [11C]Raclopride. *Journal of Cerebral Blood Flow and Metabolism*, **2003**, 280-284	7.3	5
157	OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease.		81
156	Kinfitr an open source tool for reproducible PET modelling: validation and evaluation of test-retest reliability.		2
155	Chemokine receptor 2-targeted molecular imaging in pulmonary fibrosis.		0
154	A High-Resolution In Vivo Atlas of the Human Brain Benzodiazepine Binding Site of GABAA Receptors.		3
153	In vivo characterization and quantification of neurofibrillary tau PET radioligand [18F]MK-6240 in humans from Alzheimer disease dementia to young controls.		3
152	kinfitr: Reproducible PET Pharmacokinetic Modelling in R.		4
151	CT-guided PET parametric image reconstruction using deep neural network without prior training data. **2019**,		7
150	PET imaging of brain macrophages using the peripheral benzodiazepine receptor in a macaque model of neuroAIDS. **2004**, 113, 981-989		34
149	PET imaging of brain macrophages using the peripheral benzodiazepine receptor in a macaque model of neuroAIDS. **2004**, 113, 981-9		30
148	Quantification and reliability of [C]VC - 002 binding to muscarinic acetylcholine receptors in the human lung - a test-retest PET study in control subjects. **2020**, 10, 59		3
147	Kinfitr´´an open-source tool for reproducible PET modelling: validation and evaluation of test-retest reliability. **2020**, 10, 77		7

146	[C]PIB amyloid quantification: effect of reference region selection. **2020**, 10, 123	4
145	Levodopa effects on [(11)C]raclopride binding in the resting human brain. **2015**, 4, 23	14
144	Serotonin transporter occupancy of SKL10406 in humans: comparison of pharmacokinetic-pharmacodynamic modeling methods for estimation of occupancy parameters. **2014**, 22, 83	1
143	Detection of pancreatic carcinomas by imaging lactose-binding protein expression in peritumoral pancreas using [18F]fluoroethyl-deoxylactose PET/CT. **2009**, 4, e7977	19
142	Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients. **2011**, 6, e17338	105
141	Genotype and ancestry modulate brain's DAT availability in healthy humans. **2011**, 6, e22754	46
140	Changes in striatal dopamine release associated with human motor-skill acquisition. **2012**, 7, e31728	22
139	The role of serotonin in sleep disordered breathing associated with Parkinson disease: a correlative [11C]DASB PET imaging study. **2012**, 7, e40166	28
138	Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET. **2013**, 8, e75952	19
137	Building up analgesia in humans via the endogenous □opioid system by combining placebo and active tDCS: a preliminary report. **2014**, 9, e102350	54
136	Automated movement correction for dynamic PET/CT images: evaluation with phantom and patient data. **2014**, 9, e103745	16
135	18F-Mefway PET imaging of serotonin 1A receptors in humans: a comparison with 18F-FCWAY. **2015**, 10, e0121342	9
134	Striatal Dopamine D2/D3 Receptor Availability Is Associated with Executive Function in Healthy Controls but Not Methamphetamine Users. **2015**, 10, e0143510	7
133	In Vivo Evaluation of Blood Based and Reference Tissue Based PET Quantifications of [11C]DASB in the Canine Brain. **2016**, 11, e0148943	3
132	Normal Striatal Vesicular Acetylcholine Transporter Expression in Tourette Syndrome. **2017**, 4,	11
131	tacmagic: Positron emission tomography analysis in R. **2019**, 4, 1281	1
130	Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder. **2006**, 2, 467-73	5
129	Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging. **2016**, 23, 1818-69	110

128	Unidirectional Influx and Net Accumulation of PIB. **2008**, 2, 114-25	44
127	[German Society of Nuclear Medicine procedure guideline on beta-amyloid brain PET imaging]. **2016**, 55, 129-37	3
126	Occupancy of 7 Nicotinic Acetylcholine Receptors in the Brain by Tropisetron: A Positron Emission Tomography Study Using [(11)C]CHIBA-1001 in Healthy Human Subjects. **2011**, 9, 111-6	21
125	Direct Reconstruction of Linear Parametric Images from Dynamic PET Using Nonlocal Deep Image Prior. **2021**, PP,	3
124	Comparison of Invasive and Non-invasive Estimation of [C]PBR28 Binding in Non-human Primates. **2021**, 1	
123	[F](2,4)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma. **2021**, 11, 760732	2
122	In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer's disease. **2021**, 13, 178	1
121	Measuring the BP of Four Dopaminergic Tracers Utilizing a Tissue Input Function. **2001**, 131-137	
120	A New Linear Parametric Imaging Algorithm Derived from a Simplified Reference Tissue Model for Ligand-Receptor Dynamic PET Studies. **2002**, 33-39	
119	Comparison between Bolus and Infusion [11C]Raclopride Delivery for the Quantification of Dopamine Release. **2002**, 71-75	
118	Quantification of Opioid Receptor Binding with [11C]Carfentanil. **2002**, 27-32	
117	Wavelet Methods for the Mathematical and Statistical Modeling of PET Images. **2002**, 101-106	
116	61. Analysis of 123I-FPCIT (DATSCANTM) binding in normal volunteers and in patients with Parkinson disease. **2002**, 23, 401-402	
115	Techniques for Parametric Imaging. **2008**, 137-IX	1
114	Molecular Imaging in Biology and Pharmacology. **2008**, 457-XLV	
113	Tracer Kinetic Modeling: Basics and Concepts. **2010**, 333-351	1
112	Imaging in Neurology Research III: Focus on Neurotransmitter Imaging. **2011**, 515-541	
111	Imaging in Drug Development. **2014**, 731-746	

110	Imaging of Central Benzodiazepine Receptors in Chronic Cerebral Ischemia. **2014**, 213-227	
109	Imaging Histamine Receptors Using PET and SPECT. **2014**, 331-376	
108	Tracer Kinetic Modelling. **2014**, 59-73	
107	Intra-bone Marrow Transplant (IBMT) of Cord Blood (CB) Cells: A Transplant Approach that Tries to Optimize Seeding Efficiency and Trafficking of Hematopoietic Stem Cells (HSCs). **2014**, 203-210	
106	Encyclopedia of Computational Neuroscience. **2014**, 1-14	
105	Kinetic Modeling: Achieving Computer Platform Independence with Java. **1998**, 353-356	
104	Computational Methods for Molecular Imaging. **2015**, 3-14	
103	Hybrid Imaging in Cerebrovascular Disease: Ischemic Stroke. **2016**, 251-262	
102	Enhanced detection of early photons in time-domain optical tomography using dead-time characteristics of SPADs. **2016**,	
101	Dynamic PET imaging. **2017**, 321-335	
100	Molecular Contrast Agents. **2018**, 131-184	
99	First in-human PET study of 3 novel tau radiopharmaceuticals: [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948.	1
98	Observation of magnetic susceptibility changes within the thalamus: a comparative study between healthy and Parkinson disease afflicted cynomolgus monkeys using 7 T MRI. **2019**, 10,	
97	Sex differences in methylphenidate-induced dopamine increases in ventral striatum. **2021**,	1
96	Fronto-striatal dopamine D2 receptor availability is associated with cognitive variability in older individuals with low dopamine integrity. **2021**, 11, 21089	
95	Effects of placebo administration on immune mechanisms and relationships with central endogenous opioid neurotransmission. **2021**,	0
94	Cerebral A adenosine receptor availability in female and male participants and its relationship to sleep. **2021**, 245, 118695	0
93	Metacognition, cortical thickness, and tauopathy in aging.	

92	Compartmental Modeling in Emission Tomography. **2020**, 1-20	
91	Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial. **2021**, 11, 559	5
90	Maternal Dopamine Encodes Affective Signals of Human Infants. **2021**,	0
89	Reading abilities and dopamine D/D receptor availability: An inverted U-shaped association in subjects with schizophrenia. **2021**, 223, 105046	0
88	A common polymorphism in the dopamine transporter gene predicts working memory performance and in vivo dopamine integrity in aging. **2021**, 245, 118707	0
87	Genome-wide association, Mendelian Randomization and polygenic risk score studies converge on a role of β-amyloid and APOE locus in Parkinson disease.	
86	Quantitative Analysis of Amyloid β Deposition in Patients with Alzheimer's Disease Using Positron Emission Tomography. 220-230	1
85	[F]MPPF and [F]FDG μPET imaging in rats: impact of transport and restraint stress. **2020**, 10, 112	2
84	Alzheimer's pathology is associated with dedifferentiation of functional memory networks in aging.	
83	Tracer Kinetic Modelling. **2021**, 37-52	
82	The Use of Small Animal Molecular Imaging (μPET) Exemplified in a Neurobiological Pathology. **2021**, 57-92	
81	Imaging of Central Benzodiazepine Receptors in Chronic Cerebral Ischemia. **2021**, 245-264	
80	18F-AV-1451 positron emission tomography in neuropathological substrates of corticobasal syndrome. **2021**, 144, 266-277	1
79	Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. **2007**, 32, 86-102	188
78	Serotonin2A receptor binding potential in people with aggressive and violent behaviour. **2008**, 33, 499-508	35
77	Role of Kinetic Modeling in Biomedical Imaging. **2008**, 28, 57-63	3
76	FDG- and amyloid-PET in Alzheimer's disease: is the whole greater than the sum of the parts?. **2011**, 55, 250-64	29
75	Limitations of SRTM, Logan graphical method, and equilibrium analysis for measuring transient dopamine release with [(11)C]raclopride PET. **2013**, 3, 247-60	13

74	How to design PET experiments to study neurochemistry: application to alcoholism. **2014**, 87, 33-54	7
73	Positron Emission Tomography (PET) and Graphical Kinetic Data Analysis of the Dopamine Neurotransmitter System: An Exercise for an Undergraduate Laboratory Course. **2014**, 12, A114-22	
72	PET brain kinetics studies of (11)C-ITMM and (11)C-ITDM,radioprobes for metabotropic glutamate receptor type 1, in a nonhuman primate. **2014**, 4, 260-9	14
71	Comparison of Kinetic Models for Dual-Tracer Receptor Concentration Imaging in Tumors. **2014**, 1,	12
70	Simplified estimation of binding parameters based on image-derived reference tissue models for dopamine transporter bindings in non-human primates using [F]FE-PE2I and PET. **2017**, 7, 246-254	3
69	Quantification methods comparison in brain F-FDOPA PET. **2019**, 9, 274-281	1
68	Evaluation of quantitative modeling methods in whole-body, dynamic [C]-erlotinib PET. **2021**, 11, 143-153	0
67	Compartmental Modeling in Emission Tomography. **2021**, 1431-1450	
66	Four-modality imaging of unmedicated subjects with schizophrenia: F-fluorodeoxyglucose and F-fallypride PET, diffusion tensor imaging, and MRI.. **2021**, 320, 111428	1
65	The Aged Striatum: Evidence of Molecular and Structural Changes Using a Longitudinal Multimodal Approach in Mice.. **2022**, 14, 795132	0
64	Risk for opioid misuse in chronic pain patients is associated with endogenous opioid system dysregulation.. **2022**, 12, 20	0
63	Spatial and temporal dynamics of HDACs class IIa following mild traumatic brain injury in adult rats.. **2022**,	0
62	Validation and test-retest repeatability performance of parametric methods for [C]UCB-J PET.. **2022**, 12, 3	
61	Upregulation of Striatal Metabotropic Glutamate Receptor Subtype 1 (mGluR1) in Rats with Excessive Glutamate Release Induced by N-Acetylcysteine.. **2022**, 40, 26	0
60	First-in-human evaluation of F-SMBT-1, a novel F-labeled MAO-B PET tracer for imaging reactive astrogliosis.. **2022**,	5
59	Evaluation of the □synuclein PET radiotracer (d3)-[11C]MODAG-001 in pigs.	
58	Spontaneous remyelination in lesions protects the integrity of surrounding tissues over time in multiple sclerosis.. **2022**,	0
57	Epileptic discharges initiate from brain areas with elevated accumulation of □amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors.. **2022**, 4, fcac023	0

56	Lack of association between bridging integrator 1 () rs744373 polymorphism and tau-PET load in cognitively intact older adults.. **2022**, 8, e12227	
55	Rates of amyloid deposition indicate widespread simultaneous accumulation throughout the brain.. **2022**, 115, 1-11	
54	Identifying Mild Alzheimer's Disease With First 30-Min C-PiB PET Scan.. **2022**, 14, 785495	
53	Application of correlated component analysis to dynamic PET time-activity curves denoising. **2021**, 2021, 3680-3683	
52	NRM 2021 Abstract Booklet.. *Journal of Cerebral Blood Flow and Metabolism*, **2021**, 41, 11-309	7.3
51	Brain opioid segments and striatal patterns of dopamine release induced by naloxone and morphine. **2021**,	1
50	PET imaging of brain aromatase in humans and rhesus monkeys by C-labeled cetrozole analogs. **2021**, 11, 23623	0
49	Trapping of Nicotinic Acetylcholine Receptor Ligands Assayed by in vitro Cellular Studies and in vivo PET Imaging.	0
48	Simultaneous Multifactor Bayesian Analysis (SiMBA) of PET Time Activity Curve Data.. **2022**, 256, 119195	1
47	Beyond monoamines: I. Novel targets and radiotracers for Positron emission tomography imaging in psychiatric disorders.. **2022**,	1
46	Dynamic regulation of neural variability during working memory reflects dopamine, functional integration, and decision-making.	1
45	Continuous but not intermittent theta burst stimulation decreases striatal dopamine release and cortical excitability.. **2022**, 354, 114106	
44	Cortical D1 and D2 dopamine receptor availability modulate methylphenidate-induced changes in brain activity and functional connectivity. **2022**, 5,	
43	Imaging the fetal nonhuman primate brain with SV2A positron emission tomography (PET).	
42	Rejection sensitivity and mu opioid receptor dynamics associated with mood alterations in response to social feedback. **2022**, 111505	0
41	Design and Synthesis of Aryl-Piperidine Derivatives as Potent and Selective PET Tracers for Cholesterol 24-Hydroxylase (CH24H).	
40	Unsupervised PET Logan Parametric Image Estimation Using Conditional Deep Image Prior. **2022**, 102519	1
39	Mu Opioid Receptor Dynamics in Healthy Volunteers with a History of Childhood Maltreatment.	

38	Kinetic Models for PET/SPECT Imaging. **2022**, 1753-1763	
37	Metacognition, cortical thickness, and tauopathy in aging. **2022**,	
36	Longitudinal Dopamine D2 Receptor Changes and Cerebrovascular Health in Aging. 10.1212/WNL.0000000000200891	
35	Neuronal Alterations in Secondary Thalamic Degeneration Due to Cerebral Infarction: A 11 C-Flumazenil Positron Emission Tomography Study.	0
34	A quantitative in vivo imaging platform for tracking pathological tau depositions and resultant neuronal death in a mouse model.	0
33	Measurement of Striatal Dopamine Release Induced by Neuropsychological Stimulation in Positron Emission Tomography With Dual Injections of [11C]Raclopride. 13,	
32	Design and synthesis of aryl-piperidine derivatives as potent and selective PET tracers for cholesterol 24-hydroxylase (CH24H). **2022**, 240, 114612	0
31	Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals. **2022**, 7,	0
30	Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts.	4
29	Dopamine D 2/3 receptor availabilities in striatal and extrastriatal regions of the adult human brain: Comparison of four methods of analysis.	
28	Trapping of Nicotinic Acetylcholine Receptor Ligands Assayed by in vitro Cellular Studies and in vivo PET Imaging. JN-RM-2484-21	
27	Evaluation of an image-derived input function for kinetic modeling of nicotinic acetylcholine receptor-binding PET ligands.	
26	Evaluation of the □synuclein PET radiotracer (d3)-[11C]MODAG-001 in pigs. **2022**,	1
25	Four decades of mapping and quantifying neuroreceptors at work in vivo by positron emission tomography. 16,	0
24	Preliminary evidence for the sequentially mediated effect of racism-related stress on pain sensitivity through sleep disturbance and corticolimbic opioid receptor function. **2022**,	0
23	Serotonin and dopamine transporter availability in social anxiety disorder after combined treatment with escitalopram and cognitive-behavioral therapy. **2022**, 12,	0
22	Assessment of cholesterol homeostasis in the living human brain. **2022**, 14,	0
21	A pilot study comparing myelin measurements from myelin water imaging and 11C-PIB PET in multiple sclerosis. **2022**, 68, 104238	0

20	Advances in molecular neuroimaging methodology. **2023**, 53-66	0
19	Kinetic evaluation and assessment of longitudinal changes in reference region and extracerebral [18F]MK-6240 PET uptake. 0271678X2211421	1
18	Dosimetry and efficacy of a tau PET tracer [18F]MK-6240 in Japanese healthy elderly and patients with Alzheimer disease.	0
17	Noninvasive Quantitative PET Imaging in Humans of the Pancreatic Beta-Cell Mass Biomarkers VMAT2 and Dopamine D2/D3 Receptors In Vivo. **2023**, 61-74	0
16	Reduced D 2 / D 3 Receptor Binding and Glucose Metabolism in a Macaque Model of Huntington's Disease.	0
15	Dopamine D2/3 Receptor Availabilities in Striatal and Extrastriatal Regions of the Adult Human Brain: Comparison of Four Methods of Analysis.	0
14	Molecular Imaging of the Association between Serotonin Degeneration and Beta-Amyloid Deposition in Mild Cognitive Impairment. **2023**, 103322	0
13	Serotonin transporter availability in physically aggressive personality disordered patients: associations with trait and state aggression, and response to fluoxetine.	0
12	Automated production of [11C]butyrate for keto body PET imaging. **2023**, 108315	0
11	NiftyPAD - Novel Python Package for Quantitative Analysis of Dynamic PET Data.	0
10	Methods to Verify Expression and Function of DREADDs Using PET. **2023**, 263-273	0
9	Synthesis and Biological Evaluation of Enantiomerically Pure (R)- and (S)-[18F]OF-NB1 for Imaging the GluN2B Subunit-Containing NMDA receptors.	0
8	Acute nicotine exposure blocks aromatase in the limbic brain of healthy women: A [11C]cetrozole PET study. **2023**, 123, 152381	0
7	Discontinuation of methylphenidate after long-term exposure in nonhuman primates. **2023**, 97, 107173	0
6	Small-animal PET study for noninvasive quantification of transmembrane AMPA receptor regulatory protein (TARP) in the brain. 0271678X2311520	0
5	An empirical measure of resilience explains individual differences in the effect of tau pathology on memory change in aging. **2023**, 3, 229-237	0
4	In vivo Brain Estrogen Receptor Expression By Neuroendocrine Aging And Relationships With Gray Matter Volume, Bio-Energetics, and Clinical Symptomatology.	0
3	Development of near-infrared paired-agent imaging for in vivo quantification of drug receptor occupancy in tumor. **2023**,	0

2	Parkinson's disease. **2023**, 337-361	0
1	Dynamics of AMPA receptors regulate epileptogenesis in patients with epilepsy. **2023**, 101020	0